Globus Medical (GMED) 10-K 14 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Billions, except Share data, unless otherwise specified	Dec. 31, 2013	Feb. 14, 2014	Jun. 30, 2013
DEI [Abstract]	'	'	'
Entity Registrant Name	'GLOBUS MEDICAL INC	'	'
Entity Central Index Key	'0001237831	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	93,711,759	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$0.90

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$89,962	$212,400
Short-term marketable securities	148,962	0
Accounts receivable, net of allowances of $1,581 and $961, respectively	62,414	53,496
Inventories	70,350	62,310
Prepaid expenses and other current assets	5,080	3,020
Income taxes receivable	2,723	5,105
Deferred income taxes	37,317	23,779
Total current assets	416,808	360,110
Property and equipment, net	64,150	61,089
Long-term marketable securities	36,528	0
Intangible assets, net	29,537	9,585
Goodwill	18,372	15,372
Other assets	909	977
Total assets	566,304	447,133
LIABILITIES AND EQUITY	'	'
Accounts payable	10,073	9,991
Accounts payable to related-party	2,656	2,556
Accrued expenses	51,125	25,003
Income taxes payable	2,358	523
Business acquisition liabilities, current	1,730	1,435
Total current liabilities	67,942	39,508
Business acquisition liabilities, net of current portion	15,528	9,909
Deferred income taxes	6,385	7,714
Other liabilities	4,089	3,500
Total liabilities	93,944	60,631
Commitments and contingencies (Note 14)	'	'
Equity:	'	'
Common stock; $0.001 par value. Authorized 785,000 shares; issued and outstanding 93,443 and 91,270 shares at December 31, 2013 and 2012, respectively	93	91
Additional paid-in capital	153,987	136,501
Accumulated other comprehensive loss	-1,009	-767
Retained earnings	319,289	250,677
Total equity	472,360	386,502
Total liabilities and equity	$566,304	$447,133

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Current Assets:	'	'
Allowance for doubtful accounts	$1,581	$961
Equity:	'	'
Common stock, par value (in usd per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	785,000,000	785,000,000
Common stock, shares issued	93,442,753	91,270,064
Common stock, shares outstanding	93,442,753	91,270,064

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Sales	$434,459	$385,994	$331,478
Cost of goods sold	100,343	75,199	68,796
Gross profit	334,116	310,795	262,682
Operating expenses:	'	'	'
Research and development	26,870	27,926	23,464
Selling, general and administrative	182,518	168,862	140,386
Provision for litigation litigation loss/(income)	23,055	-786	1,470
Total operating expenses	232,443	196,002	165,320
Operating income	101,673	114,793	97,362
Other income/(expense), net	328	-140	-413
Income before income taxes	102,001	114,653	96,949
Income tax provision	33,389	40,822	36,165
Net income	$68,612	$73,831	$60,784
Earnings per share:	'	'	'
Basic	$0.74	$0.82	$0.69
Diluted	$0.73	$0.80	$0.67
Weighted average shares outstanding:	'	'	'
Basic	92,647	89,608	88,112
Dilutive stock options	1,545	2,600	2,308
Diluted	94,192	92,208	90,420
Anti-dilutive stock equivalents excluded from weighted average calculation	1,975	2,383	2,054

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Net income	$68,612	$73,831	$60,784
Other comprehensive income/(loss):	'	'	'
Unrealized gain on marketable securities, net of tax	32	0	0
Foreign currency translation gain/(loss)	-274	435	-484
Total other comprehensive income/(loss)	-242	435	-484
Comprehensive income	$68,370	$74,266	$60,300

Consolidated_Statements_of_Equ

Consolidated Statements of Equity (USD $)	Total	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Retained Earnings
In Thousands, except Share data, unless otherwise specified
Total stockholders' equity, beginning of period at Dec. 31, 2010	$228,195	$51	$74	$102,709	($718)	$126,079
Balance, Shares at Dec. 31, 2010	'	50,691,000	73,613,000	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation	3,286	'	'	3,286	'	'
Exercise of deemed stock options	144	'	'	144	'	'
Exercise of stock options (shares)	149,000	'	149,000	'	'	'
Exercise of stock options	742	'	0	742	'	'
Tax benefit related to nonqualified stock options excercised	-170	'	'	-170	'	'
Purchase of common stock (shares)	-1,233,397	'	-1,233,000	'	'	'
Purchase of common stock	-10,021	'	-1	-3	'	-10,017
Comprehensive income	60,300	'	'	'	-484	60,784
Total stockholders' equity, end of period at Dec. 31, 2011	282,476	51	73	106,708	-1,202	176,846
Balance, Shares at Dec. 31, 2011	'	50,691,000	72,529,000	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation	4,635	'	'	4,635	'	'
Exercise of stock options (shares)	1,061,000	'	1,061,000	'	'	'
Exercise of stock options	1,504	'	1	1,503	'	'
Tax benefit related to nonqualified stock options excercised	2,661	'	'	2,661	'	'
Conversion of preferred stock in conjunction with IPO, Converted (shares)	'	-50,691,000	'	'	'	'
Conversion of preferred stock in conjunction with IPO, Converted	'	-51	'	'	'	'
Conversion of preferred stock in conjunction with IPO, Issued (shares)	'	'	15,597,000	'	'	'
Conversion of preferred stock in conjunction with IPO, Issued	0	'	15	36	'	'
Issuance of common stock from IPO, net of expenses (shares)	'	'	2,083,000	'	'	'
Issuance of common stock from IPO, net of expenses	20,960	'	2	20,958	'	'
Purchase of common stock (shares)	0	'	'	'	'	'
Comprehensive income	74,266	'	'	'	435	73,831
Total stockholders' equity, end of period at Dec. 31, 2012	386,502	0	91	136,501	-767	250,677
Balance, Shares at Dec. 31, 2012	'	0	91,270,000	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation	5,177	'	'	5,177	'	'
Exercise of stock options (shares)	2,173,000	'	2,173,000	'	'	'
Exercise of stock options	7,555	'	2	7,553	'	'
Tax benefit related to nonqualified stock options excercised	4,756	'	'	4,756	'	'
Purchase of common stock (shares)	0	'	'	'	'	'
Comprehensive income	68,370	'	'	'	-242	68,612
Total stockholders' equity, end of period at Dec. 31, 2013	$472,360	$0	$93	$153,987	($1,009)	$319,289
Balance, Shares at Dec. 31, 2013	'	0	93,443,000	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income	$68,612	$73,831	$60,784
Adjustments to reconcile net income to net cash provided by operating activities	'	'	'
Depreciation and amortization	19,397	18,108	16,949
Provision for excess and obsolete inventories	8,212	6,119	10,487
Stock-based compensation	5,177	4,635	3,286
Allowance for doubtful accounts	693	363	105
Change in deferred income taxes	-14,858	-6,079	2,057
(Increase) decrease in:	'	'	'
Accounts receivable	-9,612	-6,886	-4,672
Inventories	-16,678	-20,541	-15,280
Prepaid expenses and other assets	-597	-117	460
Increase (decrease) in:	'	'	'
Accounts payable	1,840	3,048	-1,355
Accounts payable to related party	100	1,378	-696
Accrued expenses and other liabilities	26,963	4,208	1,575
Income taxes payable/receivable	4,222	-1,548	2,710
Net cash provided by operating activities	93,471	76,519	76,410
Cash flows from investing activities:	'	'	'
Purchases of marketable securities	-240,892	0	0
Maturities of marketable securities	40,560	0	0
Sales of marketable securities	13,637	0	0
Purchases of property and equipment	-23,680	-24,684	-22,487
Acquisition of businesses	-16,775	-6,031	-7,500
Net cash used in investing activities	-227,150	-30,715	-29,987
Cash flows from financing activities:	'	'	'
Repayments of long-term debt	0	0	-5,253
Payment of business acquisition liabilities	-1,300	-1,100	-400
Net proceeds from initial public offering	0	20,960	0
Net proceeds from issuance of common stock	7,555	1,504	886
Purchase of common stock	0	0	-10,021
Excess tax benefit related to nonqualified stock options	4,756	2,661	54
Net cash provided by/(used in) financing activities	11,011	24,025	-14,734
Effect of foreign exchange rate on cash	230	-97	-722
Net increase/(decrease) in cash and cash equivalents	-122,438	69,732	30,967
Cash and cash equivalents, beginning of period	212,400	142,668	111,701
Cash and cash equivalents, end of period	89,962	212,400	142,668
Supplemental disclosures of cash flow information:	'	'	'
Interest paid	96	63	167
Income taxes paid	$38,719	$44,875	$35,721

BACKGROUND_AND_SUMMARY_OF_SIGN

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Background and Summary of Significant Accounting Policies	'
	BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) The Company
	Globus Medical, Inc. and its subsidiaries is a medical device company focused exclusively on the design, development and commercialization of musculoskeletal implants. We are currently focused on implants that promote healing in patients with spine disorders. We are an engineering-driven company with a history of rapidly developing and commercializing advanced products and procedures that assist surgeons in effectively treating their patients, respond to evolving surgeon needs and address new treatment options. Since our inception in 2003, we have launched over 120 products and offer a product portfolio addressing a broad array of spinal pathologies.
	We are headquartered in Audubon, Pennsylvania and market and sell our products through our exclusive sales force in the United States, Europe, India, South Africa, Australia, South America and the Middle East. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
	The terms the “Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, our consolidated subsidiaries.
	(b) Basis of Presentation
	The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for financial statements and with the instructions to Form 10-K and Article 10 of Regulation S-X.
	(c) Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held, as well as the consolidation of VIEs in which we are the primary beneficiary. All intercompany balances and transactions are eliminated in consolidation.
	(d) Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
	(e) Foreign Currency Translation
	The functional currency of our foreign subsidiaries is their local currency. Assets and liabilities of the foreign subsidiaries are translated at the period end currency exchange rate and revenues and expenses are translated at an average currency exchange rate for the period. The resulting foreign currency translation gains and losses are included as a component of accumulated other comprehensive income. Gains and losses arising from intercompany foreign transactions are included in other income/(expense) on the consolidated statement of operations. We recognized foreign exchange transaction losses in other income/(expense) of $0.8 million, $0.2 million, and $0.4 million for the years ended December 31, 2013, 2012, and 2011, respectively.
	(f) Cash and Cash Equivalents
	Cash and cash equivalents include cash on hand and all highly liquid investments with a maturity of three months or less when purchased.
	(g) Accounts Receivable and Allowance for Doubtful Accounts
	The majority of our accounts receivable is composed of amounts due from hospitals. We carry our accounts receivable at cost less an allowance for doubtful accounts. On a regular basis, we evaluate our accounts receivable and estimate an allowance for doubtful accounts, as needed, based on various factors such as our customers’ current credit conditions, length of time past due, and the general economy as a whole. Receivables are written off against the allowance when they are deemed uncollectible.
	(h) Concentrations of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, are primarily cash and cash equivalents and accounts receivable. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of entities comprising our customer base. We perform ongoing credit evaluations of our customers and generally do not require collateral.
	There was no customer that accounted for 10% or more of sales for the years ended December 31, 2013, 2012, and 2011, respectively.
	(i) Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper and asset-backed securities, and are classified as available-for-sale as of December 31, 2013. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
	(j) Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
	(k) Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Additions or improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation and amortization are provided using the straight-line method over the related useful lives of the assets.
	When assets are sold or otherwise disposed of, the related property, equipment, and accumulated depreciation amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.
	(l) Goodwill and Intangible Assets
	Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at a minimum on an annual basis. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount, to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. For the year ended December 31, 2013, we performed a qualitative test for impairment as permitted under Financial Accounting Standards Board (“FASB”) authoritative guidance. During the years ended December 31, 2013, 2012 and 2011, we did not record any impairment charges related to goodwill.
	Intangible assets consist of purchased in-process research and development (“IPR&D”), patents, customer relationships and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to seventeen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis.
	IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value.
	We completed our annual qualitative indefinite lived intangible asset impairment review in the fourth quarter of 2013 and determined that our intangible assets were not impaired.
	(m) Impairment of Long-Lived Assets
	We periodically evaluate the recoverability of the carrying amount of long-lived assets, which include property and equipment, as well as whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be fully recoverable. An impairment is assessed when the undiscounted future cash flows from the use and eventual disposition of an asset group are less than its carrying value. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset group. Our fair value methodology is based on quoted market prices, if available. If quoted market prices are not available, an estimate of fair value is made based on prices of similar assets or other valuation techniques including present value techniques. We reviewed our long-lived assets over the course of 2013 and recorded an immaterial impairment charge as a component of cost of goods sold.
	(n) Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.
	(o) Research and Development
	Research and development costs are expensed as incurred. Research and development costs include salaries, employee benefits, supplies, consulting services, clinical services and clinical trial costs, and facilities costs. Costs incurred in obtaining technology licenses and patents are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.
	(p) Stock-Based Compensation
	The cost for employee and non-employee director awards is measured at the grant date based on the fair value of the award. The fair value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service period (generally the vesting period of the equity award). Awards issued to non-employees are recorded at their fair value as determined in accordance with authoritative guidance, and are periodically revalued as the awards vest and are recognized as expense over the requisite service period.
	The determination of the fair value of stock options is made utilizing the Black-Scholes option-pricing model which is affected by our stock price and a number of assumptions, including expected volatility, expected term, risk-free interest rate and expected dividends. The expected volatility is based upon the historical volatility of a public company peer group over the most recent period commensurate with the estimated expected term of the stock options. The expected term of the stock options is determined utilizing the simplified method given the limited extent of our historical data. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts.
	(q) Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which such items are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established to offset any deferred tax assets if, based upon available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	Significant judgment is required in determining income tax provisions and in evaluating tax positions. We will establish additional provisions for income taxes when, despite the belief that tax positions are fully supportable, there remain certain positions that do not meet the minimum probability threshold that a tax position is more likely than not to be sustained upon examination by the taxing authority. In the normal course of business, we and our subsidiaries are examined by various federal, state, and foreign tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of the provision for income taxes. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability, and deferred taxes in the period in which the facts that give rise to a revision become known.
	(r) Derivatives
	We minimize risk from interest rate fluctuations through the normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. Derivative financial instruments are used to manage risk and are not used for trading or speculative purposes. Derivative financial instruments used for hedging purposes must be designated and effective as a hedge of the identified risk exposure at the inception of the contract. Accordingly, changes in fair value of the derivative contract must be correlated with changes in fair value of the underlying hedged item at inception of the hedge and over the life of the hedge contract. All derivatives are recorded in the consolidated balance sheet as assets or liabilities and measured at fair value. In 2011, we had an interest rate swap that did not qualify for hedge accounting and therefore the changes to the fair value of the derivative were recognized immediately in our consolidated statements of operations as a component of other income/(expense), net. The mortgage was paid in full and the interest rate swap expired in May 2011. There were no derivative financial instruments held as of December 31, 2013, 2012 and 2011.
	(s) Fair Value of Financial Instruments
	As of December 31, 2013, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature. We classify our financial assets and liabilities that are measured at fair value into one of the three categories based upon inputs used to determine fair value. See “Note 5. Fair Value Measurements” below for more details regarding inputs and classifications.
	(t) Advertising Expense
	We expense advertising costs as they are incurred. Advertising expense was $0.5 million, $0.4 million and $0.4 million, for the years ended December 31, 2013, 2012, and 2011, respectively.
	(u) Legal Costs
	We expense legal costs related to loss contingencies as incurred.
	(v) Reverse Stock Split and Initial Public Offering
	On July 9, 2012, in anticipation of our initial public offering (“IPO”), our Board approved a ratio of one share for every 3.25 shares previously held. The reverse stock split became effective on July 31, 2012. All common stock share and per-share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split. See “Note 10. Equity” below for more details regarding the IPO.
	(w) Medical Device Excise Tax
	Effective as of January 1, 2013, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively “PPACA”) imposed a medical device excise tax (“MDET”) of 2.3% on any entity that manufactures or imports certain medical devices offered for sale in the United States. We account for the MDET as a component of our cost of goods sold. For the year ended December 31, 2013, we recognized expenses of $7.2 million.
	(x) Recently Issued Accounting Pronouncements
	In February 2013, the FASB issued disclosure guidance to improve the transparency of items reclassified out of accumulated other comprehensive income to net income. The guidance requires an entity to present, in a single location, information about the amounts reclassified out of accumulated other comprehensive income, by component, including the income statement line items affected by the reclassification. Adoption of this guidance did not have a material impact on our financial position or results of operations.
	In March 2013, the FASB issued an update to clarify existing guidance for the release of cumulative translation adjustments into net income when a parent sells all or a part of its investment in a foreign entity or achieves a business combination of a foreign entity in stages. This guidance will be applied prospectively and is effective for us beginning January 1, 2014. We do not expect the adoption of this guidance to have a material impact on our financial position or results of operations.
	In July 2013, the FASB issued guidance to require standard presentation of an unrecognized tax benefit when a carryforward related to net operating losses or tax credits exists. This guidance will be applied prospectively and is effective for us beginning January 1, 2014. We do not expect the adoption of this guidance to have a material impact on our financial position or results of operations.

ACQUISTIONS

ACQUISTIONS	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Business Acquisitions	'
	ACQUISITIONS
	On December 23, 2013, we entered into an asset purchase agreement with a small robotics development company, pursuant to which we acquired substantially all of its assets for $16.8 million. In addition to the initial purchase price, we may be obligated to make a milestone payment and revenue sharing payments based upon a percentage of net sales of certain products based on the intellectual property we acquired in the transaction. The acquired company was privately held and is focused on developing a next generation surgical robotic positioning platform for spine, brain and therapeutic markets. The technology is intended to enable surgeons to perform minimally invasive and percutaneous surgical procedures with greater accuracy, safety and reproducibility than is currently available. We accounted for this purchase as a business combination, and as a result, recorded goodwill of $3.0 million. The table below represents the valuation of the assets acquired and liabilities assumed as part of this 2013 purchase:
	(In thousands)
	Identifiable intangible assets:
	In-process research & development	$	20,460
	Non-compete agreements	20
	Contingent consideration	(6,704		)	(1)
	Total identifiable net assets	13,776
	Goodwill	2,999
	Net assets acquired	$	16,775
	-1	The contingent consideration relates to the achievement of certain regulatory milestones and royalties. As of December 31, 2013, the aggregate, undiscounted amount of contingent consideration that the Company could pay related to the acquisitions ranges from zero to $14.3 million (see “Note 5. Fair Value Measurements” below).
	On July 18, 2012, we entered into an asset purchase agreement with a global medical device company, pursuant to which we acquired substantially all of its assets for $6.0 million. In addition to the initial purchase price, we may be obligated to make revenue sharing payments based upon a percentage of net sales of products we acquired from it. We accounted for this purchase as a business combination and as a result, recorded goodwill of $5.6 million. The table below represents the assets acquired and liabilities assumed as part of this 2012 purchase:
	(In thousands)
	Inventory	$	158
	Identifiable intangible assets:
	Customer relationships	120
	Non-compete agreements	80
	Patents	2,420
	Contingent consideration	(2,311		)
	Total identifiable net assets	467
	Goodwill	5,564
	Net assets acquired	$	6,031
	On January 10, 2011, we entered into an asset purchase agreement with a development-stage spinal company that was accounted for as a business combination. The acquired company was privately held and focused on developing motion preservation spinal implants. It developed ACADIA®, an anatomic facet reconstruction device designed to provide a motion preservation alternative to fusion for patients with lumbar spinal stenosis and facet degeneration. ACADIA® is currently involved in a U.S. Food and Drug Administration (“FDA”) approved investigational device exemption clinical study in the United States. In addition to an initial payment, we may be obligated to make an additional milestone payment within 30 days of approval by the FDA of pre-market approval clearance concerning the ACADIA® product.
	On September 13, 2011, we entered into an asset purchase agreement with an exclusive sales distributor that was accounted for as a business combination. In addition to the initial purchase price, we may be obligated to make additional performance payments based upon achievement of sales targets by the distributor.
	The table below illustrates the assets acquired and liabilities assumed for the $7.5 million in aggregate that was paid for the acquisitions upon closing during 2011:
	(In thousands)
	Inventory	$	1,443
	Identifiable intangible assets:
	In-process research & development	4,100
	Customer relationships	3,291
	Non-compete agreements	112
	Current liabilities	(1,728		)	(2)
	Contingent consideration	(5,007		)	(3)
	Other noncurrent liabilities	(4,519		)	(4)
	Total identifiable net assets	(2,308		)
	Goodwill	9,808
	Net assets acquired	$	7,500
	-2	Includes $1.2 million of purchase price consideration due in the 12 months after the acquisition date. The remaining $0.5 million is assumed liabilities. As of December 31, 2011, $1.2 million of cash payments due in 2012 are included in business acquisition liabilities, current on the accompanying consolidated balance sheet.
	-3	The contingent consideration relates to the achievement of certain regulatory and territory sales milestones. As of December 31, 2011, the aggregate, undiscounted amount of contingent consideration that the Company could pay related to the acquisitions ranges from zero to $7.2 million (see “Note 5. Fair Value Measurements” below).
	-4	Includes $4.1 million of purchase price consideration not paid as of the acquisition date. As of December 31, 2011, unpaid purchase price installments, net of discount, of $3.7 million are included in business acquisition liabilities, net of current portion. Cash payments of $1.2 million per year are due in 2013, 2014, and 2015 and payments of $0.8 million are due in 2016. Also includes $0.5 million for the value of a put agreement executed in connection with the September 13, 2011 acquisition, which, under the terms of the put agreement, was canceled upon the completion of our IPO during 2012 (see “Note 10. Equity” below).
	These acquisitions, which expand our product pipeline and retain key existing customer relationships, did not have a material effect on our consolidated net sales or operating income for the years ended December 31, 2013, 2012 or 2011. The assets acquired and liabilities assumed as a result of the acquisitions were included in our consolidated balance sheet as of the acquisition dates. The purchase price for each of the acquisitions was primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates. The fair value assigned to identifiable intangible assets acquired was determined primarily by using the income approach, which discounts expected future cash flows to present value using estimates and assumptions determined by management. Purchased identifiable intangible assets are amortized on a straight-line basis over their respective estimated useful lives. The excess purchase price over the value of the net tangible and identifiable intangible assets was recorded as goodwill. The goodwill from our acquisitions is expected to be deductible for tax purposes.
	The fair value of the IPR&D was determined using a relief from royalty approach, including a pre-tax royalty rate ranging between 4% and 9% and a discount rate ranging between 13.5% and 19%. IPR&D will become an amortizable asset upon completion of the projects, both of which are currently expected to be in 2016. The estimated costs to complete the IPR&D projects are approximately $23.8 million as of December 31, 2013.
	The following table provides a reconciliation of the beginning and ending balances of contingent payments associated with acquisitions during the years ended December 31, 2013 and December 31, 2012:
	(In thousands)
	Balance at December 31, 2011	$	4,928
	Purchase price contingent consideration	2,311
	Changes in fair value of contingent consideration classified in operating expenses	119
	Balance at December 31, 2012	7,358
	Purchase price contingent consideration	6,704
	Contingent payments	(5		)
	Changes in fair value of contingent consideration classified in operating expenses	120
	Balance at December 31, 2013	$	14,177

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure	'
	INTANGIBLE ASSETS
	A summary of intangible assets as of December 31, 2013 is presented below:
	(In thousands)	Weighted-		Gross			Accumulated Amortization				Intangible
		Average Amortization		Carrying							Assets, net
		Period		Amount
		(in years)
	In-process research & development	—		$	24,560		$	—			$	24,560
	Customer relationships & other intangibles	9.5		3,623			(864		)		2,759
	Patents	17		2,420			(202		)		2,218
	Total intangible assets			$	30,603		$	(1,066	)		$	29,537
	A summary of intangible assets as of December 31, 2012 is presented below:
	(In thousands)	Weighted-		Gross			Accumulated Amortization				Intangible
		Average Amortization		Carrying							Assets, net
		Period		Amount
		(in years)
	In-process research & development	—		$	4,100		$	—			$	4,100
	Customer relationships & other intangibles	9.7		3,603			(479		)		3,124
	Patents	17		2,420			(59		)		2,361
	Total intangible assets			$	10,123		$	(538	)		$	9,585
	Amortization expense was as follows:
	(in thousands)		31-Dec-13			December 31, 2012				December 31, 2011
	Intangible asset amortization expense		$	528		$	468			$	70
	Expected future intangible asset amortization as of December 31, 2013 is as follows:
	(In thousands)		Annual Amortization
	Year ending December 31:
	2014		$	531
	2015		531
	2016		528
	2017		499
	2018		476
	Thereafter		2,412
	Total		4,977

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2013
Marketable Securities [Abstract]	'
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure	'
	MARKETABLE SECURITIES
	The composition of our short-term and long-term marketable securities as of December 31, 2013 is as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	77,342	$	17	$	(15	)	$	77,344
	Corporate debt securities	Less than 1	35,525		15		(11		)	35,529
	Commercial paper	Less than 1	36,083		6		—			36,089
	Total short-term marketable securities		$	148,950	$	38	$	(26	)	$	148,962
	Long-term:
	Municipal bonds	2-Jan	$	12,304	$	13	$	(1	)	$	12,316
	Corporate debt securities	2-Jan	17,533		27		—			17,560
	Asset backed securities	2-Jan	6,651		2		(1		)	6,652
	Total long-term marketable securities		$	36,488	$	42	$	(2	)	$	36,528
	We had no short-term or long-term marketable securities as of December 31, 2012.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	FAIR VALUE MEASUREMENTS
	Under the accounting for fair value measurements and disclosures, fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:
	Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities;
	Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and
	Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques.
	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	December 31,		Level 1		Level 2	Level 3
		2013
	Cash equivalents	$	20,363	$	19,098	1,265	—
	Municipal bonds	89,660		—		89,660	—
	Corporate debt securities	53,089		—		53,089	—
	Commercial paper	36,089		—		36,089	—
	Asset-backed securities	6,652		—		6,652	—
	Contingent consideration	14,177		—		—	14,177
		Balance at
	(In thousands)	December 31,		Level 1		Level 2	Level 3
		2012
	Cash equivalents	$	96,585	$	96,585	—	—
	Contingent consideration	7,358		—		—	7,358
	Contingent consideration represents our contingent milestone, performance and revenue-sharing payment obligations related to our acquisitions and is measured at fair value and is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant, such as the probabilities associated with successfully completing clinical trials and obtaining regulatory approval, of achieving sales milestones and the period in which these milestones are expected to be achieved, as well as discount rates, which range from 3.1% to 13.5%. We assess these estimates on an ongoing basis as additional data impacting the assumptions is obtained. Changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within research and development and selling, general and administrative expenses in the consolidated statements of income.
	Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis
	The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates, with the excess recorded as goodwill. We utilize Level 3 inputs in the determination of the initial fair value. Non-financial assets such as goodwill, intangible assets, and property, plant, and equipment are subsequently measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment is recognized. We assess the impairment of intangible assets annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. The fair value of our goodwill and intangible assets is not estimated if there is no change in events or circumstances that indicate the carrying amount of an intangible asset may not be recoverable. We have not recorded impairment charges related to our business acquisitions.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	INVENTORIES
	(In thousands)	December 31, 2013		December 31, 2012
	Raw materials	$	1,369	$	2,024
	Work in process	2,820		2,410
	Finished goods	66,161		57,876
	Total	$	70,350	$	62,310

PROPERTY_EQUIPMENT

PROPERTY & EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property And Equipment	'
	PROPERTY AND EQUIPMENT
	(In thousands)	Useful Life		December 31, 2013				December 31, 2012
	Land	—		$	3,769			$	3,769
	Buildings and improvements	30		9,541				8,770
	Equipment	7-May		14,588				13,320
	Instruments	3		107,867				95,739
	Modules and cases	3		22,325				19,045
	Other property and equipment	5-Mar		5,970				6,104
				164,060				146,747
	Less: accumulated depreciation			(99,910		)		(85,658		)
	Total			$	64,150			$	61,089
	Instruments are hand-held devices used by surgeons to install implants during surgery. Modules and cases are used to store and transport the instruments and implants.
	Depreciation expense related to property and equipment was as follows:
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Depreciation	$	18,869			$	17,640			$	16,879

ACCRUED_EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	ACCRUED EXPENSES
	(In thousands)	December 31,		December 31,
		2013		2012
	Compensation and other employee-related costs	$	17,428	$	16,733
	Legal and other settlements and expenses	23,765		1,924
	Accrued non-income taxes	2,938		473
	Other	6,994		5,873
	Total accrued expenses	$	51,125	$	25,003
	The increase in legal and other settlements and expenses is primarily due to the accruals related to the two unfavorable verdicts (Synthes, Bianco) recognized during the year end December 31, 2013 (see “Note 14. Commitments and Contingencies” below for more information).

DEBT

DEBT	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt	'
	DEBT
	(a) Mortgage Loan
	In 2007, we entered into a four-year mortgage loan payable with a bank associated with our corporate headquarters in Audubon, Pennsylvania. We made monthly principal payments plus interest at a rate of LIBOR plus 1.5%. The mortgage was paid in full with a final balloon payment of $5.1 million in May 2011.
	(b) Line of Credit
	In May 2011, and as amended in March 2012 and May 2013, we entered into a credit agreement with Wells Fargo Bank related to a revolving credit facility that provides for borrowings up to $50.0 million. At our request, and with the approval of the bank, the amount of borrowings available under the revolving credit facility can be increased to $75.0 million. The revolving credit facility includes up to a $25.0 million sub-limit for letters of credit. The revolving credit facility expires in May 2015. Cash advances bear interest at our option either at a fluctuating rate per annum equal to the daily LIBOR in effect for a one-month period plus 0.75%, or a fixed rate for a one- or three-month period equal to LIBOR plus 0.75%. The credit agreement governing the revolving credit facility also subjects us to various restrictive covenants, including the requirement to maintain maximum consolidated leverage. The covenants also include limitations on our ability to repurchase shares, to pay cash dividends or to enter into a sale transaction. As of December 31, 2013, we were in compliance with all covenants under the credit agreement, there were no outstanding borrowings under the revolving credit facility and available borrowings were $50.0 million. The revolving credit facility is subject to an unused commitment fee of 0.10% of the unused portion. We may terminate the credit agreement at any time on ten days’ notice without premium or penalty.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Equity	'
	EQUITY
	Prior to June 21, 2012, of the authorized number of shares of common stock, we had 360,000,000 shares designated as Class A common stock (“Class A Common”), 309,178,636 shares designated as Class B common stock (“Class B Common”) and 10,000,000 shares designated as Class C common stock (“Class C Common”). On June 21, 2012, we amended and restated our Certificate of Incorporation, and as a result, amended the number of authorized shares. As of the amendment date, of the authorized number of shares of common stock, we had 500,000,000 shares designated as Class A Common, 275,000,000 shares designated as Class B Common and 10,000,000 shares designated as Class C Common.
	The holders of Class A Common are entitled to one vote for each share of Class A Common held. The holders of Class B Common are entitled to 10 votes for each share of Class B Common held. The holders of Class A Common and Class B Common vote together as one class of common stock. The Class C Common is nonvoting. Except for voting rights, the Class A Common, Class B Common and Class C Common have the same rights and privileges.
	In August 2012, we completed our IPO. We sold 2,083,333 shares of our Class A Common at an offering price of $12.00 per share. We recognized gross proceeds of $25.0 million and our net proceeds received after underwriting fees and offering expenses were $21.0 million.
	All common stock share and per-share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split that became effective July 31, 2012.
	Immediately prior to the closing of our IPO, we effectuated the following conversion:
	•	the automatic conversion of all shares of our Series E preferred stock to 15,597,300 shares of our Class B Common;
	•	the subsequent automatic conversion of 49,655,411 shares of our Class B Common (which reflects all such shares of Class B Common held by those who beneficially owned less than 10% of the aggregate number of all outstanding shares of our common stock) to 49,655,411 shares of our Class A Common;
	•	the automatic conversion of all shares of our Class C Common to 73,554 shares of our Class A Common; and
	•	the automatic conversion of 3,039,385 shares of Class B Common to 3,039,385 shares of Class A Common upon their sale by the selling stockholders.
	Although the number of outstanding shares of our Series E preferred stock did not change due to the reverse stock split, the rate at which shares of our Series E preferred stock converted into shares of Class B Common decreased proportionally to the reverse stock split ratio. The reverse stock split did not affect the number of shares of capital stock we are authorized to issue. As a result of the reverse stock split, the number of unreserved and issuable shares of authorized common stock increased.
	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common	Class B	Total
			Common
	December 31, 2013	66,065,197	27,377,556	93,442,753
	31-Dec-12	63,892,508	27,377,556	91,270,064
	In 2011, we repurchased 1,233,397 shares of our outstanding common stock from existing stockholders. There were no repurchases during the years ended December 31, 2013 and 2012.
	In connection with a business acquisition in 2011, we entered into a put agreement with an existing stockholder (the “Put Agreement”). Pursuant to the Put Agreement, the stockholder had the right and option to cause us to repurchase up to 25% of the stockholders’ shares on the last business day of September in each of 2014, 2015, 2016 and 2017. The put purchase price was to be determined based upon our trailing twelve months EBITDA.
	The put option was cancelable and could not be exercised any time after the earliest to occur of (i) the closing of an IPO, (ii) the date on which we enter into an agreement for a sale of the Company, as defined in the Put Agreement, and (iii) a breach event, as defined in the Put Agreement. Under the terms of the Put Agreement, we canceled the put option upon the completion of our IPO.
	Series E Preferred Stock
	Prior to our reverse stock split that became effective July 31, 2012, we had 50,691,245 shares of Series E preferred stock outstanding. As a result of the reverse split and conversion accompanying the IPO, the Series E preferred stock converted into 15,597,300 shares of common stock. For further details regarding the Series E preferred stock prior to the IPO, please refer to our prospectus filed on August 3, 2012.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	STOCK-BASED COMPENSATION
	No additional shares will be issued under our Amended and Restated 2003 Stock Plan and our 2008 Stock Plan, leaving the 2012 Equity Incentive Plan (the "2012 Plan") as the only remaining active stock plan.  The purpose of these stock plans was, and the 2012 Plan is, to provide incentive to employees, directors, and consultants of Globus.  The Plans are administered by the Board or its delegates. The number, type of option, exercise price, and vesting terms are determined by the Board or its delegates in accordance with the terms of the Plans. The options granted expire on a date specified by the Board, but generally not more than ten years from the grant date. Option grants to employees generally vest monthly over a four-year period.
	The 2012 Plan was approved by our Board in March 2012, and by our stockholders in June 2012. Under the 2012 Plan, the aggregate number of shares of Class A Common that may be issued subject to options and other awards is equal to the sum of (i) 3,076,923 shares, (ii) any shares available for issuance under the 2008 Plan as of March 13, 2012, (iii) any shares underlying awards outstanding under the 2008 Plan as of March 13, 2012 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares and (iv) starting January 1, 2013, an annual increase in the number of shares available under the 2012 Plan equal to up to 3% of the number of shares of our common and preferred stock outstanding at the end of the previous year, as determined by our Board. The number of shares that may be issued or transferred pursuant to incentive stock options under the 2012 Plan is limited to 10,769,230 shares. The shares of Class A Common covered by the 2012 Plan are authorized but unissued shares, treasury shares or shares of common stock purchased on the open market.
	As of December 31, 2013, pursuant to the 2012 Plan, there were 6,246,075 shares of Class A Common stock reserved and 4,453,236 shares of Class A Common stock available for future grants.
	The weighted average grant date per share fair values of the options awarded to employees were as follows:
			Year Ended
			December 31,				December 31,				December 31,
			2013				2012				2011
	Weighted average grant date per share fair value		$	6.34			$	5.9			$	5.14
	The fair value of the options was estimated on the date of the grant using a Black-Scholes option pricing model with the following assumptions:
		Year Ended
		December 31,						December 31,					December 31,
		2013						2012					2011
	Risk-free interest rate	0.98	%	-	1.74	%		0.9	%	-	1.1	%	1.46	%	-	2.65	%
	Expected term (years)	6.1		-	6.4			6					6
	Expected volatility	41	%	-	44	%		44	%	-	47	%	46.5	%	-	47	%
	Expected dividend yield	—%						—%					—%
	Stock option activity during the years ended December 31, 2013, 2012 and 2011 is summarized as follows:
		Option Shares (thousands)			Weighted average exercise price				Weighted average remaining contractual life (years)		Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2010	5,844			$	4.19
	Granted	1,185			10.86
	Exercised	(149	)		4.13
	Forfeited	(426	)		8.65
	Outstanding at December 31, 2011	6,454			5.14
	Granted	1,228			13.1
	Exercised	(1,061	)		1.42
	Forfeited	(368	)		9.55
	Outstanding at December 31, 2012	6,253			6.99
	Granted	1,222			14.78
	Exercised	(2,173	)		3.48
	Forfeited	(416	)		12.23
	Outstanding at December 31, 2013	4,886			$	10.04			6.9		$	49,528
	Exercisable at December 31, 2013	2,821			$	7.33			5.4		$	36,250
	We use the Black Scholes pricing model to determine the fair value of our stock options (see “Note 1. Background and Summary of Significant Accounting Policies, (p) Stock-Based Compensation” above). Subsequent to the February 2012 and March 2012 stock option grants, we reassessed the fair value of our stock options on those dates of grant by updating the assumptions and facts considered in an October 2011 valuation report upon which we relied to take into account our actual results, market conditions, comparable company results, and the timing of our anticipated IPO. On July 2, 2012, we determined that the fair value as of the February 2, 2012 grant was $12.06 and that the fair value as of the March 28, 2012 grant was $14.10, rather than $10.34 as originally determined. The impact on net income for the three months ended March 31, 2012 and June 30, 2012 was not material.
	Compensation expense related to stock options granted to employees and non-employees under the Plans and the intrinsic value of stock options exercised was as follows:
			Year Ended
	(In thousands)		December 31,				December 31,				December 31,
			2013				2012				2011
	Compensation expense related to stock options		$	5,177			$	4,635			$	3,286
	Intrinsic value of stock options exercised		25,034				12,507				969
	As of December 31, 2013, there was $10.1 million of unrecognized compensation expense related to unvested employee stock options that are expected to vest over a weighted average period of three years.
	At various dates since our formation, we sold shares of Class A Common and Class B Common to certain employees and non-employees through the receipt of promissory notes. For accounting purposes, these promissory notes are considered the issuance of an option as opposed to the sale of stock, since we did not contemporaneously document the borrower’s ability to repay the promissory notes. As a result, we have recognized compensation expense for these awards through their vesting period.
	As there were no grants for the years ended December 31, 2013, 2012, and 2011, there was no compensation expense related to these deemed options granted to employees and non-employees for those years.
	For accounting purposes, the repayment of a promissory note is considered an exercise of the deemed option. Since the shares are legally issued and outstanding, they are reflected in the accompanying consolidated statements of equity. The notes were fully repaid as of December 31, 2011.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	The components of income/(loss) before income taxes are as follows:
						Year ended
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Domestic	$	101,424			$	114,176			$	97,677
	Foreign	577				477				(728		)
	Total	$	102,001			$	114,653			$	96,949
	The components of the provision for income taxes are as follows:
						Year ended
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Current:
	Federal	$	41,741			$	40,338			$	28,846
	State	6,118				6,419				4,889
	Foreign	912				345				373
		48,771				47,102				34,108
	Deferred:
	Federal	(14,088		)		(5,510		)		2,062
	State	(1,210		)		(352		)		(52		)
	Foreign	(84		)		(418		)		47
		(15,382		)		(6,280		)		2,057
	Total	$	33,389			$	40,822			$	36,165
	A reconciliation of the statutory U.S. federal tax rate to our effective rate is as follows:
		Year ended
		31-Dec-13			December 31, 2012			December 31, 2011
	Statutory U.S. federal tax rate	35	%		35	%		35	%
	State income taxes, net of federal benefit	2.8	%		2.9	%		3.3	%
	Domestic production activities deduction	(3.5	)%		(2.3	)%		(1.5	)%
	Tax credits	(1.7	)%		(0.1	)%		(1.0	)%
	Nondeductible expenses and other	0.1	%		0.1	%		1.5	%
	Effective tax rate	32.7	%		35.6	%		37.3	%
	Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes. Significant components of our deferred income taxes are as follows:
	(In thousands)	31-Dec-13				December 31, 2012
	Deferred tax assets:
	Inventory reserve	$	19,635			$	16,288
	Accruals, reserves, and other currently not deductible	17,133				5,639
	Stock-based compensation	5,152				4,913
	Foreign net operating loss carryforwards	724				952
	Total deferred tax assets	42,644				27,792
	Valuation allowance	(327		)		(533		)
	Total deferred tax assets, net of valuation allowance	42,317				27,259
	Deferred tax liabilities:
	Depreciation and amortization	(9,759		)		(9,993		)
	Other	(1,229		)		(782		)
	Total deferred tax liabilities	(10,988		)		(10,775		)
	Net deferred tax assets	$	31,329			$	16,484
	In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not that we will realize the benefits of these deductible differences at December 31, 2013. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced. Of the amounts presented above, $0.4 million of long-term deferred tax assets is included as a component of other assets on our consolidated balance sheet as of December 31, 2013 and 2012.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
						Year ended
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Unrecognized tax benefit at the beginning of the year	$	3,500			$	2,799			$	3,845
	Additions related to current year tax positions	$	661			$	673			$	612
	Additions related to prior year tax positions	64				46				22
	Reductions related to prior year tax positions	(109		)		(18		)		(1,680		)
	Lapse of statute of limitations	(138		)		—				—
	Unrecognized tax benefit at the end of the year	3,978				3,500				2,799
	The impact of our unrecognized tax benefits to the effective income tax rate is as follows:
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Portion of total unrecognized tax benefits that, if recognized, would affect the effective income tax rate	$	1,184			$	747			$	591
	Interest and penalties are recorded in the statement of operations as provision for income taxes. The total interest and penalties recorded in the statement of operations was nominal for the years ended December 31, 2013, 2012 and 2011. Our uncertain tax benefits could increase in the next twelve months as we continue our current transfer pricing policies and deduct additional tax credits. We are unable to estimate a range of reasonably possible changes in our uncertain tax benefits in the next twelve months. We are currently under IRS audit for the 2011 tax year, but are unable to predict when the audit will conclude or any findings that may require settlement. The tax years that remained subject to examination by a major tax jurisdiction as of December 31, 2013 were 2009 and beyond for India and Switzerland; 2010 and beyond for the United States, Belgium, Germany, Poland and South Africa; 2011 and beyond for the United Kingdom, Denmark, Sweden, Israel and Australia.
	On January 2, 2013, the American Taxpayer Relief Act of 2012 (the “ATRA”) was signed into law. One of the provisions of the ATRA was a reinstatement and extension of the research and experimentation tax credit from January 1, 2012 through December 31, 2013. However, as of December 31, 2012 no benefit could be recognized for this tax credit due to the passage of the ATRA in 2013. As the passage of the ATRA occurred in 2013, the entire reinstated credit for the year ended December 31, 2012 of $0.9 million was recognized in 2013 in accordance with accounting guidance.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2013
Leases, Operating [Abstract]	'
Leases	'
	LEASES
	The Company leases certain equipment and office facilities under operating leases. As of December 31, 2013, minimum future rental payments under operating leases for each of the next five years are as follows:
	(In thousands)
	Year ending December 31:
	2014	$	733
	2015	422
	2016	262
	2017	102
	2018	46
	Thereafter	43
	Total	$	1,608
	Rent expense related to all operating leases recognized as a component of selling, general and administrative expenses was as follows:
				Year ended
	(In thousands)	31-Dec-13		December 31, 2012		December 31, 2011
	Rent expense	$	424	$	419	$	317

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	We are involved in a number of proceedings, legal actions, and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within our control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions prohibiting us from engaging in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. We record a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the matters discussed, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position or cash flows.
	Compliance-Civil Monetary Penalties Proceeding-NUBONE®
	In February 2012, we and David Paul, our Chairman and Chief Executive Officer (“CEO”), reached a settlement with the FDA to resolve an administrative complaint alleging Food, Drug and Cosmetic Act violations regarding the marketing of our product, NUBONE®. We voluntarily discontinued the manufacturing and sale of NUBONE® in 2010 despite a history of safe use. The settlement did not constitute an admission of liability or fault by either us or our CEO.
	A settlement agreement of $1.0 million was finalized and paid in February 2012. The full settlement amount was accrued (and included in the provision for litigation settlements on the income statement) as of December 31, 2011.
	Patent Infringement Litigation-PIVOT® & Non-PIVOT® Systems
	Warsaw Orthopedic, Inc. had filed suit (the original complaint was filed in September 2006) against us in the United States District Court for the Eastern District of Pennsylvania alleging, among other matters, that we are infringing the claims of nine patents (the “Competitor Patents”) in connection with our manufacture, sale, and use of certain products, including the PIVOT® MIS System. Warsaw sought damages and injunctive relief against any Globus product held to infringe on one or more Competitor Patents.
	A jury trial began in September 2008 on the claims regarding the PIVOT® MIS System with the remainder of the claims being settled shortly thereafter. The jury found that the PIVOT® MIS System infringed certain Competitor Patents. On July 16, 2009, the court awarded damages to Warsaw in the amount of $2.8 million, but denied Warsaw’s claim for injunctive relief. Both parties appealed the court’s ruling. Warsaw voluntarily dismissed its appeal. The appeal was decided on January 26, 2011 with a finding that certain claims of the Competitor Patents are invalid and certain claims are valid. As a result of the appeals court ruling, the damages awarded by the trial court stand. After the appeal ruling, the parties stipulated to conclude the litigation.
	As of December 31, 2010, we had accrued $3.0 million based on the trial court damages award for the PIVOT® matters and for ongoing royalty payments in 2011. In June 2011, we paid $3.0 million, including post-judgment interest.
	N-Spine, Synthes and Depuy Synthes Litigation
	In April 2010, N-Spine, Inc. and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. N-Spine, the patent owner, and Synthes USA, a licensee of the subject patent, allege that we infringe one or more claims of the patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. N-Spine and Synthes USA seek injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. This matter was stayed on July 14, 2011 pending the resolution of an inter partes reexamination on the asserted patent granted by the U.S. Patent and Trademark Office (“USPTO”) in February 2011. In December 2011, the examiner withdrew the original grounds of rejection of the asserted patent and we appealed the examiner’s decision. In January 2014, the USPTO ruled on the appeal finding certain claims rejected in view of the prior art and affirming certain other claims. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	In a related matter, on January 8, 2014, Depuy Synthes Products, LLC (“Depuy Synthes”) filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Depuy Synthes alleges that we infringe one or more claims of the asserted patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. Depuy Synthes seeks injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. This matter is in its very early stages, and the probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC Litigation
	In July 2011, Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Synthes USA LLC, the patent owner, Synthes USA Products, LLC, a licensee to manufacture products of the subject patents, and Synthes USA Sales LLC, a licensee to sell products of the subject patents, allege that we infringe one or more claims of three patents by making, using, offering for sale or selling our COALITION®, INDEPENDENCE® and INTERCONTINENTAL® products. As a result of the acquisition of Synthes, Inc. by Johnson & Johnson, a motion was filed to change the plaintiff in this matter to DePuy Synthes in February 2013. On June 14, 2013, the jury in this case returned a verdict, finding that prior versions of the three products we previously sold did infringe on DePuy Synthes’ patents and awarding monetary damages in the amount of $16.0 million. The jury also upheld the validity of DePuy Synthes’ patents. There was no finding of willful infringement by Globus.
	We do not expect the verdict to impact our ability to conduct our business or to have any material impact on our future revenues. As this lawsuit involved only three products that are no longer part of our product portfolio, this verdict is not expected to impair our ability to sell any of our future products.
	We believe the facts and the law do not support the jury’s findings of infringement and patent validity and are seeking to overturn the verdict in post-trial motions with the District Court and, if necessary, we will continue to do so through the appeals process.
	For the year ended December 31, 2013, we accrued $19.5 million in damages and other litigation-related costs related to this case, of which $1.3 million was included in provision for litigation loss (cost of goods sold, due to a write off of certain inventory which will not be sold due to the verdict) and $18.2 million was included in provision for litigation loss (operating expense).
	L5 Litigation
	In December 2009, we filed suit in the Court of Common Pleas of Montgomery County, Pennsylvania against our former exclusive independent distributor L5 Surgical, LLC and its principals, seeking an injunction and declaratory judgment concerning certain restrictive covenants made to L5 by its sales representatives. L5 brought counterclaims against us alleging tortious interference, unfair competition and conspiracy. The injunction phase was resolved in September 2010, and this matter is now in the discovery phase of litigation on the underlying damages claims. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	NuVasive Infringement Litigation
	In October 2010, NuVasive, Inc. filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. NuVasive, the patent owner, alleges that we infringe one or more claims of three patents by making, using, offering for sale or selling our MARS™ 3V retractor for use in certain lateral fusion procedures. NuVasive seeks injunctive relief and an unspecified amount in damages. The litigation is currently in the dispositive motions phase. We intend to defend our rights vigorously. Additionally, we sought inter partes reexaminations of the three patents asserted by NuVasive in the USPTO, which were granted in April 2012. In August 2012, the examiner withdrew the original grounds of rejection of the patents asserted by NuVasive, and we are in the process of appealing the examiner’s decision. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	NuVasive Employee Litigation
	We have hired several employees who were formerly employed by NuVasive, Inc. In July 2011, NuVasive filed suit against us in the District Court of Travis County Texas alleging that our hiring of one named former employee and other unnamed former employees constitutes tortious interference with its contracts with those employees, and with prospective business relationships, as well as aiding and abetting the breach of fiduciary duty. NuVasive is seeking compensatory damages, permanent injunction, punitive damages and attorneys’ fees. Trial is currently scheduled for May 2014. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Bianco Litigation
	On March 21, 2012, Sabatino Bianco filed suit against us in the Federal District Court for the Eastern District of Texas claiming that we misappropriated his trade secret and confidential information and improperly utilized it in developing our CALIBER® product. Bianco alleges that we engaged in misappropriation of trade secrets, breach of contract, unfair competition, fraud and theft and seeks correction of inventorship, injunctive relief and exemplary damages. On April 20, 2012, Bianco filed a motion for a preliminary injunction, seeking to enjoin us from making, using, selling, importing or offering for sale our CALIBER® product. On November 15, 2012, the court denied Bianco’s motion for preliminary injunction. On October 1, 2013, Bianco amended his complaint to include that his trade secrets and confidential information were also used improperly in developing our RISE® and CALIBER-L®products.
	On January 17, 2014, the jury in this case returned a verdict in favor of Bianco on a claim of misappropriation of trade secret. We have accrued the verdict amount of $4.3 million as of December 31, 2013. The jury found against Bianco on the claims of breach of contract and disgorgement of profits. The court granted our motion for judgment as a matter of law and dismissed Bianco’s claims for unfair competition, fraud, and exemplary damages, and Bianco abandoned the claim of misappropriation of confidential information. Judgment has not yet been entered in this case. Bianco’s claims of correction of inventorship, unjust enrichment, and permanent injunctive relief were not submitted to the jury and will be decided by the court. On March 7, 2014, the court denied Bianco’s claim for correction of inventorship and ruled he is not entitled to be named as a co-inventor on any of the patents at issue, and also denied his claim for unjust enrichment. Bianco’s claim for permanent injunctive relief will be decided at a date yet to be determined. Bianco’s claim for future damages, if any are permitted, will be determined by the court in a separate proceeding after judgment is entered.
	We do not expect the verdict to impact our ability to conduct our business or to have any material impact on our future revenues. We believe the facts and the law do not support the jury’s findings of misappropriation of trade secret and will seek to overturn the verdict in post-trial motions with the District Court and, if necessary, through the appeals process.
	Altus Partners, LLC Litigation
	On February 20, 2013, Altus Partners, LLC filed suit against us in the U.S. District Court for the Eastern District of Pennsylvania for patent infringement.  Altus Partners, LLC alleges that we infringe one or more claims of U.S. Patent No. 8,162,989, which issued on April 24, 2012, by making, using, offering for sale or selling our REVERE®, TRANSITION® and REVOLVE® products.  Altus Partners seeks injunctive relief and an unspecified amount in damages. This matter was stayed on March 4, 2014 pending the resolution of an inter partes review of the asserted patent which we filed on February 11, 2014 with the USPTO. While we intend to defend our rights vigorously, the probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	In addition, we are subject to legal proceedings arising in the ordinary course of business.

RETIREMENT_BENEFIT_PLANS

RETIREMENT BENEFIT PLANS	12 Months Ended
	Dec. 31, 2013
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'
Retirement Benefit Plans	'
	PLANS
	We sponsor a 401(k) Plan covering all eligible U.S. employees. Under the 401(k) Plan, we make nondiscretionary matching contributions at the rate of 100% of employee’s contributions up to a maximum annual contribution of $6,000 per eligible employee, limited to 3% of the employee’s compensation for the period.
	Additionally, we contribute to various foreign retirement benefit plans required by local law or coordinated with government sponsored plans which cover many of our international employees. The benefits offered under these plans are reflective of local customs and practices in the countries concerned.
	Company contributions to these retirement plans were as follows:
		Year ended
	(In thousands)	31-Dec-13		December 31, 2012		December 31, 2011
	401(k) and other retirement plan contributions	$	2,106	$	1,055	$	944

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related-Party Transactions	'
	RELATED-PARTY TRANSACTIONS
	We have contracted with a third-party manufacturer in which certain of our senior management and significant stockholders have or had ownership interests and leadership positions.
	We have purchased the following amounts of products and services from the supplier:
		Year Ended
	(In thousands)	December 31, 2013		December 31,		December 31,
				2012		2011
	Purchases from related-party supplier	$	20,039	$	20,159	$	17,685
	As of December 31, 2013 and December 31, 2012, we had $2.7 million and $2.6 million of accounts payable due to the supplier.

SEGMENT_AND_GEOGRAPHIC_INFORMA

SEGMENT AND GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment And Geographic Information	'
	SEGMENT AND GEOGRAPHIC INFORMATION
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We globally manage the business within one reportable segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Products are sold principally in the United States.
	The following table represents total sales by geographic area, based on the location of the customer:
		Year Ended
	(In thousands)	December 31,		December 31,		December 31,
		2013		2012		2011
	United States	$	396,615	$	355,609	$	311,024
	International	37,844		30,385		20,454
	Total sales	$	434,459	$	385,994	$	331,478
	We classify our products into two categories: Innovative Fusion products and Disruptive Technology products. The following table represents total sales by product category:
		Year Ended
	(In thousands)	December 31,		December 31,		December 31,
		2013		2012		2011
	Innovative Fusion	$	254,033	$	238,723	$	224,356
	Disruptive Technology	180,426		147,271		107,122
	Total sales	$	434,459	$	385,994	$	331,478

QUARTERLY_FINANCIAL_DATA_unaud

QUARTERLY FINANCIAL DATA (unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data (unaudited)	'
	QUARTERLY FINANCIAL DATA (unaudited)
		(unaudited)
	(In thousands, except per share amounts)	March 31,		June 30,		September 30,		December 31,
		2013		2013		2013		2013
	Sales	$	105,018	$	107,009	$	107,187	$	115,245
	Gross profit	81,525		82,248		81,872		88,471
	Net income	19,891		7,426		20,310		20,985
	Net earnings per common share - basic	0.22		0.08		0.22		0.22
	Net earnings per common share - diluted	0.21		0.08		0.22		0.22
		(unaudited)
	(In thousands, except per share amounts)	March 31,		June 30,		September 30,		December 31,
		2012		2012		2012		2012
	Sales	$	94,717	$	95,977	$	94,764	$	100,536
	Gross profit	76,326		77,598		75,892		80,979
	Net income	17,576		19,001		16,487		20,767
	Net earnings per common share - basic	0.2		0.22		0.18		0.23
	Net earnings per common share - diluted	0.19		0.21		0.18		0.22

VALUATION_ACCOUNTS_AND_QUALIFY

VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Valuation Accounts and Qualifying Accounts	'
	VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS
	Allowance for doubtful accounts:
	(In thousands)	Beginning of period		Additions		Write-offs			End of period
	Year ended December 31, 2011	$	608	$	105	$	(111	)	$	602
	Year ended December 31, 2012	602		363		(4		)	961
	Year ended December 31, 2013	$	961	$	693	$	(73	)	$	1,581
	Deferred tax valuation allowance:
	(In thousands)	Beginning of period		Additions		Write-offs			End of period
	Year ended December 31, 2011	$	911	$	238	$	—		$	1,149
	Year ended December 31, 2012	1,149		—		(616		)	533
	Year ended December 31, 2013	$	533	$	—	$	(206	)	$	327

BACKGROUND_AND_SUMMARY_OF_SIGN1

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held, as well as the consolidation of VIEs in which we are the primary beneficiary. All intercompany balances and transactions are eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
Foreign Currency Translation	'
	Foreign Currency Translation
	The functional currency of our foreign subsidiaries is their local currency. Assets and liabilities of the foreign subsidiaries are translated at the period end currency exchange rate and revenues and expenses are translated at an average currency exchange rate for the period. The resulting foreign currency translation gains and losses are included as a component of accumulated other comprehensive income. Gains and losses arising from intercompany foreign transactions are included in other income/(expense) on the consolidated statement of operations.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents include cash on hand and all highly liquid investments with a maturity of three months or less when purchased.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	The majority of our accounts receivable is composed of amounts due from hospitals. We carry our accounts receivable at cost less an allowance for doubtful accounts. On a regular basis, we evaluate our accounts receivable and estimate an allowance for doubtful accounts, as needed, based on various factors such as our customers’ current credit conditions, length of time past due, and the general economy as a whole. Receivables are written off against the allowance when they are deemed uncollectible.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, are primarily cash and cash equivalents and accounts receivable. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of entities comprising our customer base. We perform ongoing credit evaluations of our customers and generally do not require collateral.
	There was no customer that accounted for 10% or more of sales for the years ended December 31, 2013, 2012, and 2011, respectively.
Marketable Securities	'
	Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper and asset-backed securities, and are classified as available-for-sale as of December 31, 2013. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Additions or improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation and amortization are provided using the straight-line method over the related useful lives of the assets.
	When assets are sold or otherwise disposed of, the related property, equipment, and accumulated depreciation amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at a minimum on an annual basis. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount, to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. For the year ended December 31, 2013, we performed a qualitative test for impairment as permitted under Financial Accounting Standards Board (“FASB”) authoritative guidance. During the years ended December 31, 2013, 2012 and 2011, we did not record any impairment charges related to goodwill.
	Intangible assets consist of purchased in-process research and development (“IPR&D”), patents, customer relationships and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to seventeen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis.
	IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	We periodically evaluate the recoverability of the carrying amount of long-lived assets, which include property and equipment, as well as whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be fully recoverable. An impairment is assessed when the undiscounted future cash flows from the use and eventual disposition of an asset group are less than its carrying value. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset group. Our fair value methodology is based on quoted market prices, if available. If quoted market prices are not available, an estimate of fair value is made based on prices of similar assets or other valuation techniques including present value techniques.
Revenue Recognition	'
	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.
Research and Development	'
	Research and Development
	Research and development costs are expensed as incurred. Research and development costs include salaries, employee benefits, supplies, consulting services, clinical services and clinical trial costs, and facilities costs. Costs incurred in obtaining technology licenses and patents are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.
Stock-Based Compensation	'
	Stock-Based Compensation
	The cost for employee and non-employee director awards is measured at the grant date based on the fair value of the award. The fair value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service period (generally the vesting period of the equity award). Awards issued to non-employees are recorded at their fair value as determined in accordance with authoritative guidance, and are periodically revalued as the awards vest and are recognized as expense over the requisite service period.
	The determination of the fair value of stock options is made utilizing the Black-Scholes option-pricing model which is affected by our stock price and a number of assumptions, including expected volatility, expected term, risk-free interest rate and expected dividends. The expected volatility is based upon the historical volatility of a public company peer group over the most recent period commensurate with the estimated expected term of the stock options. The expected term of the stock options is determined utilizing the simplified method given the limited extent of our historical data. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts.
Income Taxes	'
	Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which such items are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established to offset any deferred tax assets if, based upon available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	Significant judgment is required in determining income tax provisions and in evaluating tax positions. We will establish additional provisions for income taxes when, despite the belief that tax positions are fully supportable, there remain certain positions that do not meet the minimum probability threshold that a tax position is more likely than not to be sustained upon examination by the taxing authority. In the normal course of business, we and our subsidiaries are examined by various federal, state, and foreign tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of the provision for income taxes. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability, and deferred taxes in the period in which the facts that give rise to a revision become known.
Derivatives	'
	Derivatives
	We minimize risk from interest rate fluctuations through the normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. Derivative financial instruments are used to manage risk and are not used for trading or speculative purposes. Derivative financial instruments used for hedging purposes must be designated and effective as a hedge of the identified risk exposure at the inception of the contract. Accordingly, changes in fair value of the derivative contract must be correlated with changes in fair value of the underlying hedged item at inception of the hedge and over the life of the hedge contract. All derivatives are recorded in the consolidated balance sheet as assets or liabilities and measured at fair value.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	As of December 31, 2013, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature. We classify our financial assets and liabilities that are measured at fair value into one of the three categories based upon inputs used to determine fair value.
Advertising Expense	'
	Advertising Expense
	We expense advertising costs as they are incurred.
Legal costs	'
	Legal Costs
	We expense legal costs related to loss contingencies as incurred.
Medical Device Excise Tax	'
	Medical Device Excise Tax
	Effective as of January 1, 2013, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively “PPACA”) imposed a medical device excise tax (“MDET”) of 2.3% on any entity that manufactures or imports certain medical devices offered for sale in the United States. We account for the MDET as a component of our cost of goods sold.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In February 2013, the FASB issued disclosure guidance to improve the transparency of items reclassified out of accumulated other comprehensive income to net income. The guidance requires an entity to present, in a single location, information about the amounts reclassified out of accumulated other comprehensive income, by component, including the income statement line items affected by the reclassification. Adoption of this guidance did not have a material impact on our financial position or results of operations.
	In March 2013, the FASB issued an update to clarify existing guidance for the release of cumulative translation adjustments into net income when a parent sells all or a part of its investment in a foreign entity or achieves a business combination of a foreign entity in stages. This guidance will be applied prospectively and is effective for us beginning January 1, 2014. We do not expect the adoption of this guidance to have a material impact on our financial position or results of operations.
	In July 2013, the FASB issued guidance to require standard presentation of an unrecognized tax benefit when a carryforward related to net operating losses or tax credits exists. This guidance will be applied prospectively and is effective for us beginning January 1, 2014. We do not expect the adoption of this guidance to have a material impact on our financial position or results of operations.

ACQUISTIONS_Tables

ACQUISTIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Schedule of Assets Acquired and Liabilities Assumed	'
	The table below represents the valuation of the assets acquired and liabilities assumed as part of this 2013 purchase:
	(In thousands)
	Identifiable intangible assets:
	In-process research & development	$	20,460
	Non-compete agreements	20
	Contingent consideration	(6,704		)	(1)
	Total identifiable net assets	13,776
	Goodwill	2,999
	Net assets acquired	$	16,775
	-1	The contingent consideration relates to the achievement of certain regulatory milestones and royalties. As of December 31, 2013, the aggregate, undiscounted amount of contingent consideration that the Company could pay related to the acquisitions ranges from zero to $14.3 million (see “Note 5. Fair Value Measurements” below).
	On July 18, 2012, we entered into an asset purchase agreement with a global medical device company, pursuant to which we acquired substantially all of its assets for $6.0 million. In addition to the initial purchase price, we may be obligated to make revenue sharing payments based upon a percentage of net sales of products we acquired from it. We accounted for this purchase as a business combination and as a result, recorded goodwill of $5.6 million. The table below represents the assets acquired and liabilities assumed as part of this 2012 purchase:
	(In thousands)
	Inventory	$	158
	Identifiable intangible assets:
	Customer relationships	120
	Non-compete agreements	80
	Patents	2,420
	Contingent consideration	(2,311		)
	Total identifiable net assets	467
	Goodwill	5,564
	Net assets acquired	$	6,031
	On January 10, 2011, we entered into an asset purchase agreement with a development-stage spinal company that was accounted for as a business combination. The acquired company was privately held and focused on developing motion preservation spinal implants. It developed ACADIA®, an anatomic facet reconstruction device designed to provide a motion preservation alternative to fusion for patients with lumbar spinal stenosis and facet degeneration. ACADIA® is currently involved in a U.S. Food and Drug Administration (“FDA”) approved investigational device exemption clinical study in the United States. In addition to an initial payment, we may be obligated to make an additional milestone payment within 30 days of approval by the FDA of pre-market approval clearance concerning the ACADIA® product.
	On September 13, 2011, we entered into an asset purchase agreement with an exclusive sales distributor that was accounted for as a business combination. In addition to the initial purchase price, we may be obligated to make additional performance payments based upon achievement of sales targets by the distributor.
	The table below illustrates the assets acquired and liabilities assumed for the $7.5 million in aggregate that was paid for the acquisitions upon closing during 2011:
	(In thousands)
	Inventory	$	1,443
	Identifiable intangible assets:
	In-process research & development	4,100
	Customer relationships	3,291
	Non-compete agreements	112
	Current liabilities	(1,728		)	(2)
	Contingent consideration	(5,007		)	(3)
	Other noncurrent liabilities	(4,519		)	(4)
	Total identifiable net assets	(2,308		)
	Goodwill	9,808
	Net assets acquired	$	7,500
	-2	Includes $1.2 million of purchase price consideration due in the 12 months after the acquisition date. The remaining $0.5 million is assumed liabilities. As of December 31, 2011, $1.2 million of cash payments due in 2012 are included in business acquisition liabilities, current on the accompanying consolidated balance sheet.
	-3	The contingent consideration relates to the achievement of certain regulatory and territory sales milestones. As of December 31, 2011, the aggregate, undiscounted amount of contingent consideration that the Company could pay related to the acquisitions ranges from zero to $7.2 million (see “Note 5. Fair Value Measurements” below).
	-4	Includes $4.1 million of purchase price consideration not paid as of the acquisition date. As of December 31, 2011, unpaid purchase price installments, net of discount, of $3.7 million are included in business acquisition liabilities, net of current portion. Cash payments of $1.2 million per year are due in 2013, 2014, and 2015 and payments of $0.8 million are due in 2016. Also includes $0.5 million for the value of a put agreement executed in connection with the September 13, 2011 acquisition, which, under the terms of the put agreement, was canceled upon the completion of our IPO during 2012 (see “Note 10. Equity” below).
Contingent Consideration Rollforward Activity	'
	The following table provides a reconciliation of the beginning and ending balances of contingent payments associated with acquisitions during the years ended December 31, 2013 and December 31, 2012:
	(In thousands)
	Balance at December 31, 2011	$	4,928
	Purchase price contingent consideration	2,311
	Changes in fair value of contingent consideration classified in operating expenses	119
	Balance at December 31, 2012	7,358
	Purchase price contingent consideration	6,704
	Contingent payments	(5		)
	Changes in fair value of contingent consideration classified in operating expenses	120
	Balance at December 31, 2013	$	14,177

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Intangible Assets Disclosure [Abstract]	'
Intangible Assets Acquired as Part of Business Combination	'
	A summary of intangible assets as of December 31, 2013 is presented below:
	(In thousands)	Weighted-		Gross			Accumulated Amortization				Intangible
		Average Amortization		Carrying							Assets, net
		Period		Amount
		(in years)
	In-process research & development	—		$	24,560		$	—			$	24,560
	Customer relationships & other intangibles	9.5		3,623			(864		)		2,759
	Patents	17		2,420			(202		)		2,218
	Total intangible assets			$	30,603		$	(1,066	)		$	29,537
	A summary of intangible assets as of December 31, 2012 is presented below:
	(In thousands)	Weighted-		Gross			Accumulated Amortization				Intangible
		Average Amortization		Carrying							Assets, net
		Period		Amount
		(in years)
	In-process research & development	—		$	4,100		$	—			$	4,100
	Customer relationships & other intangibles	9.7		3,603			(479		)		3,124
	Patents	17		2,420			(59		)		2,361
	Total intangible assets			$	10,123		$	(538	)		$	9,585
Schedule of intangible asset amortization expense	'
	Amortization expense was as follows:
	(in thousands)		31-Dec-13			December 31, 2012				December 31, 2011
	Intangible asset amortization expense		$	528		$	468			$	70
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	'
	Expected future intangible asset amortization as of December 31, 2013 is as follows:
	(In thousands)		Annual Amortization
	Year ending December 31:
	2014		$	531
	2015		531
	2016		528
	2017		499
	2018		476
	Thereafter		2,412
	Total		4,977

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2013
Marketable Securities [Abstract]	'
Marketable Securities	'
	The composition of our short-term and long-term marketable securities as of December 31, 2013 is as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	77,342	$	17	$	(15	)	$	77,344
	Corporate debt securities	Less than 1	35,525		15		(11		)	35,529
	Commercial paper	Less than 1	36,083		6		—			36,089
	Total short-term marketable securities		$	148,950	$	38	$	(26	)	$	148,962
	Long-term:
	Municipal bonds	2-Jan	$	12,304	$	13	$	(1	)	$	12,316
	Corporate debt securities	2-Jan	17,533		27		—			17,560
	Asset backed securities	2-Jan	6,651		2		(1		)	6,652
	Total long-term marketable securities		$	36,488	$	42	$	(2	)	$	36,528

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis	'
	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	December 31,		Level 1		Level 2	Level 3
		2013
	Cash equivalents	$	20,363	$	19,098	1,265	—
	Municipal bonds	89,660		—		89,660	—
	Corporate debt securities	53,089		—		53,089	—
	Commercial paper	36,089		—		36,089	—
	Asset-backed securities	6,652		—		6,652	—
	Contingent consideration	14,177		—		—	14,177
		Balance at
	(In thousands)	December 31,		Level 1		Level 2	Level 3
		2012
	Cash equivalents	$	96,585	$	96,585	—	—
	Contingent consideration	7,358		—		—	7,358

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	(In thousands)	December 31, 2013		December 31, 2012
	Raw materials	$	1,369	$	2,024
	Work in process	2,820		2,410
	Finished goods	66,161		57,876
	Total	$	70,350	$	62,310

PROPERTY_EQUIPMENT_Tables

PROPERTY & EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property And Equipment	'
	(In thousands)	Useful Life		December 31, 2013				December 31, 2012
	Land	—		$	3,769			$	3,769
	Buildings and improvements	30		9,541				8,770
	Equipment	7-May		14,588				13,320
	Instruments	3		107,867				95,739
	Modules and cases	3		22,325				19,045
	Other property and equipment	5-Mar		5,970				6,104
				164,060				146,747
	Less: accumulated depreciation			(99,910		)		(85,658		)
	Total			$	64,150			$	61,089
Schedule Of Depreciation Of Property And Equipment	'
	Depreciation expense related to property and equipment was as follows:
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Depreciation	$	18,869			$	17,640			$	16,879

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	(In thousands)	December 31,		December 31,
		2013		2012
	Compensation and other employee-related costs	$	17,428	$	16,733
	Legal and other settlements and expenses	23,765		1,924
	Accrued non-income taxes	2,938		473
	Other	6,994		5,873
	Total accrued expenses	$	51,125	$	25,003

EQUITY_Tables

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of Issued and Outstanding Shares by Class	'
	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common	Class B	Total
			Common
	December 31, 2013	66,065,197	27,377,556	93,442,753
	31-Dec-12	63,892,508	27,377,556	91,270,064

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Grants in Period, Weighted Average Grant Date Fair Value	'
	The weighted average grant date per share fair values of the options awarded to employees were as follows:
			Year Ended
			December 31,				December 31,				December 31,
			2013				2012				2011
	Weighted average grant date per share fair value		$	6.34			$	5.9			$	5.14
Fair Value of Options, Assumptions Schedule	'
	The fair value of the options was estimated on the date of the grant using a Black-Scholes option pricing model with the following assumptions:
		Year Ended
		December 31,						December 31,					December 31,
		2013						2012					2011
	Risk-free interest rate	0.98	%	-	1.74	%		0.9	%	-	1.1	%	1.46	%	-	2.65	%
	Expected term (years)	6.1		-	6.4			6					6
	Expected volatility	41	%	-	44	%		44	%	-	47	%	46.5	%	-	47	%
	Expected dividend yield	—%						—%					—%
Summary of Stock Option Activity	'
	Stock option activity during the years ended December 31, 2013, 2012 and 2011 is summarized as follows:
		Option Shares (thousands)			Weighted average exercise price				Weighted average remaining contractual life (years)		Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2010	5,844			$	4.19
	Granted	1,185			10.86
	Exercised	(149	)		4.13
	Forfeited	(426	)		8.65
	Outstanding at December 31, 2011	6,454			5.14
	Granted	1,228			13.1
	Exercised	(1,061	)		1.42
	Forfeited	(368	)		9.55
	Outstanding at December 31, 2012	6,253			6.99
	Granted	1,222			14.78
	Exercised	(2,173	)		3.48
	Forfeited	(416	)		12.23
	Outstanding at December 31, 2013	4,886			$	10.04			6.9		$	49,528
	Exercisable at December 31, 2013	2,821			$	7.33			5.4		$	36,250
Stock Option Compensation Expense and Intrinsic Value Schedule	'
	Compensation expense related to stock options granted to employees and non-employees under the Plans and the intrinsic value of stock options exercised was as follows:
			Year Ended
	(In thousands)		December 31,				December 31,				December 31,
			2013				2012				2011
	Compensation expense related to stock options		$	5,177			$	4,635			$	3,286
	Intrinsic value of stock options exercised		25,034				12,507				969

INCOME_TAXES_Income_Taxes_Tabl

INCOME TAXES Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income (loss) before Income Tax, Domestic and Foreign	'
	The components of income/(loss) before income taxes are as follows:
						Year ended
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Domestic	$	101,424			$	114,176			$	97,677
	Foreign	577				477				(728		)
	Total	$	102,001			$	114,653			$	96,949
Schedule of Components Provision for Income Taxes	'
	The components of the provision for income taxes are as follows:
						Year ended
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Current:
	Federal	$	41,741			$	40,338			$	28,846
	State	6,118				6,419				4,889
	Foreign	912				345				373
		48,771				47,102				34,108
	Deferred:
	Federal	(14,088		)		(5,510		)		2,062
	State	(1,210		)		(352		)		(52		)
	Foreign	(84		)		(418		)		47
		(15,382		)		(6,280		)		2,057
	Total	$	33,389			$	40,822			$	36,165
U.S. Federal Tax Rate To Effective Rate Reconciliation	'
	A reconciliation of the statutory U.S. federal tax rate to our effective rate is as follows:
		Year ended
		31-Dec-13			December 31, 2012			December 31, 2011
	Statutory U.S. federal tax rate	35	%		35	%		35	%
	State income taxes, net of federal benefit	2.8	%		2.9	%		3.3	%
	Domestic production activities deduction	(3.5	)%		(2.3	)%		(1.5	)%
	Tax credits	(1.7	)%		(0.1	)%		(1.0	)%
	Nondeductible expenses and other	0.1	%		0.1	%		1.5	%
	Effective tax rate	32.7	%		35.6	%		37.3	%
Schedule of Components of Deferred Income Taxes	'
	Significant components of our deferred income taxes are as follows:
	(In thousands)	31-Dec-13				December 31, 2012
	Deferred tax assets:
	Inventory reserve	$	19,635			$	16,288
	Accruals, reserves, and other currently not deductible	17,133				5,639
	Stock-based compensation	5,152				4,913
	Foreign net operating loss carryforwards	724				952
	Total deferred tax assets	42,644				27,792
	Valuation allowance	(327		)		(533		)
	Total deferred tax assets, net of valuation allowance	42,317				27,259
	Deferred tax liabilities:
	Depreciation and amortization	(9,759		)		(9,993		)
	Other	(1,229		)		(782		)
	Total deferred tax liabilities	(10,988		)		(10,775		)
	Net deferred tax assets	$	31,329			$	16,484
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	'
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
						Year ended
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Unrecognized tax benefit at the beginning of the year	$	3,500			$	2,799			$	3,845
	Additions related to current year tax positions	$	661			$	673			$	612
	Additions related to prior year tax positions	64				46				22
	Reductions related to prior year tax positions	(109		)		(18		)		(1,680		)
	Lapse of statute of limitations	(138		)		—				—
	Unrecognized tax benefit at the end of the year	3,978				3,500				2,799
Impact of Unrecognized Tax Benefits to Effective Income Tax Rate	'
	The impact of our unrecognized tax benefits to the effective income tax rate is as follows:
	(In thousands)	31-Dec-13				December 31, 2012				December 31, 2011
	Portion of total unrecognized tax benefits that, if recognized, would affect the effective income tax rate	$	1,184			$	747			$	591

LEASES_Tables

LEASES (Tables)	12 Months Ended
	Dec. 31, 2013
Leases, Operating [Abstract]	'
Schedule of Minimum Future Rental Payments Under Operating Leases	'
	As of December 31, 2013, minimum future rental payments under operating leases for each of the next five years are as follows:
	(In thousands)
	Year ending December 31:
	2014	$	733
	2015	422
	2016	262
	2017	102
	2018	46
	Thereafter	43
	Total	$	1,608
Schedule of Rent Expense for Operating Leases	'
	Rent expense related to all operating leases recognized as a component of selling, general and administrative expenses was as follows:
				Year ended
	(In thousands)	31-Dec-13		December 31, 2012		December 31, 2011
	Rent expense	$	424	$	419	$	317

RETIREMENT_BENEFIT_PLANS_Table

RETIREMENT BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 31, 2013
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'
Company Contributions To Retirement Benefit Plans	'
	Company contributions to these retirement plans were as follows:
		Year ended
	(In thousands)	31-Dec-13		December 31, 2012		December 31, 2011
	401(k) and other retirement plan contributions	$	2,106	$	1,055	$	944

RELATEDPARTY_TRANSACTIONS_Tabl

RELATED-PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions	'
	We have purchased the following amounts of products and services from the supplier:
		Year Ended
	(In thousands)	December 31, 2013		December 31,		December 31,
				2012		2011
	Purchases from related-party supplier	$	20,039	$	20,159	$	17,685

SEGMENT_AND_GEOGRAPHIC_INFORMA1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Revenue from External Customers By Geographical Area International and Domestic	'
	The following table represents total sales by geographic area, based on the location of the customer:
		Year Ended
	(In thousands)	December 31,		December 31,		December 31,
		2013		2012		2011
	United States	$	396,615	$	355,609	$	311,024
	International	37,844		30,385		20,454
	Total sales	$	434,459	$	385,994	$	331,478
Revenue from External Customers by Products and Services	'
	The following table represents total sales by product category:
		Year Ended
	(In thousands)	December 31,		December 31,		December 31,
		2013		2012		2011
	Innovative Fusion	$	254,033	$	238,723	$	224,356
	Disruptive Technology	180,426		147,271		107,122
	Total sales	$	434,459	$	385,994	$	331,478

QUARTERLY_FINANCIAL_DATA_unaud1

QUARTERLY FINANCIAL DATA (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information	'
		(unaudited)
	(In thousands, except per share amounts)	March 31,		June 30,		September 30,		December 31,
		2013		2013		2013		2013
	Sales	$	105,018	$	107,009	$	107,187	$	115,245
	Gross profit	81,525		82,248		81,872		88,471
	Net income	19,891		7,426		20,310		20,985
	Net earnings per common share - basic	0.22		0.08		0.22		0.22
	Net earnings per common share - diluted	0.21		0.08		0.22		0.22
		(unaudited)
	(In thousands, except per share amounts)	March 31,		June 30,		September 30,		December 31,
		2012		2012		2012		2012
	Sales	$	94,717	$	95,977	$	94,764	$	100,536
	Gross profit	76,326		77,598		75,892		80,979
	Net income	17,576		19,001		16,487		20,767
	Net earnings per common share - basic	0.2		0.22		0.18		0.23
	Net earnings per common share - diluted	0.19		0.21		0.18		0.22

VALUATION_ACCOUNTS_AND_QUALIFY1

VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS (Tables)	12 Months Ended
	Dec. 31, 2012
Valuation and Qualifying Accounts Disclosure	'
Summary of Valuation Allowance [Table Text Block]	'
	Allowance for doubtful accounts:
	(In thousands)	Beginning of period		Additions		Write-offs			End of period
	Year ended December 31, 2011	$	608	$	105	$	(111	)	$	602
	Year ended December 31, 2012	602		363		(4		)	961
	Year ended December 31, 2013	$	961	$	693	$	(73	)	$	1,581
	Deferred tax valuation allowance:
	(In thousands)	Beginning of period		Additions		Write-offs			End of period
	Year ended December 31, 2011	$	911	$	238	$	—		$	1,149
	Year ended December 31, 2012	1,149		—		(616		)	533
	Year ended December 31, 2013	$	533	$	—	$	(206	)	$	327

BACKGROUND_AND_SUMMARY_OF_SIGN2

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 09, 2012
Summary of Significant Accounting Policies	'	'	'	'
Foreign exchange gain/(loss)	($0.80)	($0.20)	($0.40)	'
Advertising expense	0.5	0.4	0.4	'
Board approved reverse stock split ratio	'	'	'	3.25
Medical Device Excise Tax Percentage	2.30%	'	'	'
Minimum	'	'	'	'
Summary of Significant Accounting Policies	'	'	'	'
Number of Products Launched Since Inception	120	'	'	'
Estimated useful life of finite-lived intangible assets	'1 year	'	'	'
Maximum	'	'	'	'
Summary of Significant Accounting Policies	'	'	'	'
Estimated useful life of finite-lived intangible assets	'17 years	'	'	'
Cost of Goods, Total	'	'	'	'
Summary of Significant Accounting Policies	'	'	'	'
Medical Device Excise Tax	$7.20	'	'	'

ACQUISTIONS_Textuals_Details

ACQUISTIONS (Textuals) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 23, 2013	Jul. 18, 2012	Dec. 31, 2011	Sep. 13, 2011	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013
			Acquisition 2013	Acquisition 2012	Acquisitions 2011	Other Noncurrent Liabilities	Other Noncurrent Liabilities	In-process Research and Development	Minimum	Maximum
							Acquisitions 2011		In-process Research and Development	In-process Research and Development
Business Acquisition	'	'	'	'	'	'	'	'	'	'
Milestone payment, number of days due subsequent to FDA approval	'	'	'	'	'	'	'	'30 days	'	'
Current portion of purchase price consideration	'	'	'	'	$1,200,000	'	'	'	'	'
Range of aggregate undiscounted contingent consideration from acquisitions, maximum	'	'	14,300,000	'	7,200,000	'	'	'	'	'
Noncurrent portion of purchase price consideration, discounted	'	'	'	'	'	4,100,000	3,700,000	'	'	'
Purchase price consideration due 2013	'	'	'	'	1,200,000	'	'	'	'	'
Purchase price consideration due 2014	'	'	'	'	1,200,000	'	'	'	'	'
Purchase price consideration due 2015	'	'	'	'	1,200,000	'	'	'	'	'
Purchase price consideration due 2016	'	'	'	'	800,000	'	'	'	'	'
Put Agreement value	'	'	'	'	'	'	500,000	'	'	'
Liabilities assumed	'	'	'	'	500,000	'	'	'	'	'
Net assets acquired	'	'	16,775,000	6,031,000	7,500,000	'	'	'	'	'
Goodwill	18,372,000	15,372,000	2,999,000	5,564,000	9,808,000	'	'	'	'	'
Pre tax royalty rate	'	'	'	'	'	'	'	'	4.00%	9.00%
Discount rate	'	'	'	'	'	'	'	'	13.50%	19.00%
In process research and development, cost to complete	$23,800,000	'	'	'	'	'	'	'	'	'

ACQUISTIONS_Assets_Acquired_an

ACQUISTIONS (Assets Acquired and Liabilities) (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 23, 2013

Jul. 18, 2012

Dec. 31, 2011

Dec. 23, 2013

Dec. 31, 2011

Jul. 18, 2012

Dec. 31, 2011

Dec. 23, 2013

Jul. 18, 2012

Dec. 31, 2011

Jul. 18, 2012

In Thousands, unless otherwise specified

Acquisition 2013

Acquisition 2012

Acquisitions 2011

In-process Research and Development

In-process Research and Development

Customer Relationships

Customer Relationships

Non-compete Agreements

Non-compete Agreements

Non-compete Agreements

Patents

Acquisition 2013

Acquisitions 2011

Acquisition 2012

Acquisitions 2011

Acquisition 2013

Acquisition 2012

Acquisitions 2011

Acquisition 2012

Business Acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory

'

'

'

$158

$1,443

'

'

'

'

'

'

'

'

Identifiable intangible assets:

'

'

'

'

'

20,460

4,100

120

3,291

20

80

112

2,420

Current liabilities

'

'

'

'

-1,728

[1]

'

'

'

'

'

'

'

'

Contingent consideration

'

'

-6,704

[2]

-2,311

-5,007

[3]

'

'

'

'

'

'

'

'

Other noncurrent liabilities

'

'

'

'

-4,519

[4]

'

'

'

'

'

'

'

'

Total identifiable net assets

'

'

13,776

467

-2,308

'

'

'

'

'

'

'

'

Goodwill

18,372

15,372

2,999

5,564

9,808

'

'

'

'

'

'

'

'

Net assets acquired

'

'

$16,775

$6,031

$7,500

'

'

'

'

'

'

'

'

[1]

Includes $1.2 million of purchase price consideration due in the 12 months after the acquisition date. The remaining $0.5 million is assumed liabilities. As of December 31, 2011, $1.2 million of cash payments due in 2012 are included in business acquisition liabilities, current on the accompanying consolidated balance sheet.

[2]

The contingent consideration relates to the achievement of certain regulatory milestones and royalties. As of December 31, 2013, the aggregate, undiscounted amount of contingent consideration that the Company could pay related to the acquisitions ranges from zero to $14.3 million (see bNote 5. Fair Value Measurementsb below).

[3]

The contingent consideration relates to the achievement of certain regulatory and territory sales milestones. As of December 31, 2011, the aggregate, undiscounted amount of contingent consideration that the Company could pay related to the acquisitions ranges from zero to $7.2 million (see bNote 5. Fair Value Measurementsb below).

[4]

Includes $4.1 million of purchase price consideration not paid as of the acquisition date. As of December 31, 2011, unpaid purchase price installments, net of discount, of $3.7 million are included in business acquisition liabilities, net of current portion. Cash payments of $1.2 million per year are due in 2013, 2014, and 2015 and payments of $0.8 million are due in 2016. Also includes $0.5 million for the value of a put agreement executed in connection with the September 13, 2011 acquisition, which, under the terms of the put agreement, was canceled upon the completion of our IPO during 2012 (see bNote 10. Equityb below).

ACQUISTIONS_Contingent_Conside

ACQUISTIONS (Contingent Consideration Payment Rollforward) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Contingent Consideration Payment [Roll Forward]	'	'
Business Combination, Contingent Consideration, Liability	$7,358	$4,928
Purchase price contingent consideration	6,704	2,311
Contingent payments	-5	'
Changes in fair value of contingent consideration classified in operating expenses	120	119
Business Combination, Contingent Consideration, Liability	$14,177	$7,358

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Acquired Intangible Assets	'	'	'
Intangible Assets, Gross Carrying Amount	$30,603	$10,123	'
Accumulated Amortization	-1,066	-538	'
Intangible asset amortization expense	528	468	70
Intangible assets, net	29,537	9,585	'
Finite-lived intangible assets, net	4,977	'	'
Customer relationships & other intangibles	'	'	'
Acquired Intangible Assets	'	'	'
Weighted average amortization period	'9 years 6 months	'9 years 8 months	'
Gross carrying amount	3,623	3,603	'
Accumulated Amortization	-864	-479	'
Finite-lived intangible assets, net	2,759	3,124	'
Patents	'	'	'
Acquired Intangible Assets	'	'	'
Weighted average amortization period	'17 years	'17 years	'
Gross carrying amount	2,420	2,420	'
Accumulated Amortization	-202	-59	'
Finite-lived intangible assets, net	2,218	2,361	'
In-process Research and Development	'	'	'
Acquired Intangible Assets	'	'	'
Indefinite-lived intangible assets	$24,560	$4,100	'

INTANGIBLE_ASSETS_Expected_Fut

INTANGIBLE ASSETS Expected Future Amortization of Acquired Intangible Assets (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]	'
Year ending December 31, 2014	$531
Year ending December 31, 2015	531
Year ending December 31, 2016	528
Year ending December 30, 2017	499
Year ending December 31, 2018	476
Thereafter	2,412
Finite-lived intangible assets, net	$4,977

MARKETABLE_SECURITIES_Details

MARKETABLE SECURITIES (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Short-term Marketable Securities	'
Schedule of Marketable Securities	'
Marketable Securities, Amortized Cost Basis	$148,950
Marketable Securities, Gross Unrealized Gain	38
Marketable Securities, Gross Unrealized Loss	-26
Marketable Securities, Fair Value	148,962
Short-term Marketable Securities | Municipal Bonds	'
Schedule of Marketable Securities	'
Marketable Securities, Amortized Cost Basis	77,342
Marketable Securities, Gross Unrealized Gain	17
Marketable Securities, Gross Unrealized Loss	-15
Marketable Securities, Fair Value	77,344
Short-term Marketable Securities | Municipal Bonds | Maximum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'1 year
Short-term Marketable Securities | Corporate Debt Securities	'
Schedule of Marketable Securities	'
Marketable Securities, Amortized Cost Basis	35,525
Marketable Securities, Gross Unrealized Gain	15
Marketable Securities, Gross Unrealized Loss	-11
Marketable Securities, Fair Value	35,529
Short-term Marketable Securities | Corporate Debt Securities | Maximum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'1 year
Short-term Marketable Securities | Commercial Paper	'
Schedule of Marketable Securities	'
Marketable Securities, Amortized Cost Basis	36,083
Marketable Securities, Gross Unrealized Gain	6
Marketable Securities, Gross Unrealized Loss	0
Marketable Securities, Fair Value	36,089
Short-term Marketable Securities | Commercial Paper | Maximum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'1 year
Long-term Marketable Securities	'
Schedule of Marketable Securities	'
Marketable Securities, Amortized Cost Basis	36,488
Marketable Securities, Gross Unrealized Gain	42
Marketable Securities, Gross Unrealized Loss	-2
Marketable Securities, Fair Value	36,528
Long-term Marketable Securities | Municipal Bonds	'
Schedule of Marketable Securities	'
Marketable Securities, Amortized Cost Basis	12,304
Marketable Securities, Gross Unrealized Gain	13
Marketable Securities, Gross Unrealized Loss	-1
Marketable Securities, Fair Value	12,316
Long-term Marketable Securities | Municipal Bonds | Minimum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'1 year
Long-term Marketable Securities | Municipal Bonds | Maximum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'2 years
Long-term Marketable Securities | Corporate Debt Securities	'
Schedule of Marketable Securities	'
Marketable Securities, Amortized Cost Basis	17,533
Marketable Securities, Gross Unrealized Gain	27
Marketable Securities, Gross Unrealized Loss	0
Marketable Securities, Fair Value	17,560
Long-term Marketable Securities | Corporate Debt Securities | Minimum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'1 year
Long-term Marketable Securities | Corporate Debt Securities | Maximum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'2 years
Long-term Marketable Securities | Asset-backed Securities	'
Schedule of Marketable Securities	'
Marketable Securities, Amortized Cost Basis	6,651
Marketable Securities, Gross Unrealized Gain	2
Marketable Securities, Gross Unrealized Loss	-1
Marketable Securities, Fair Value	$6,652
Long-term Marketable Securities | Asset-backed Securities | Minimum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'1 year
Long-term Marketable Securities | Asset-backed Securities | Maximum	'
Schedule of Marketable Securities	'
Marketable Securities, Contractual Maturity	'2 years

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (Fair Value, Measurements, Recurring, USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Estimate of Fair Value Measurement	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	$20,363	$96,585
Contingent consideration	14,177	7,358
Estimate of Fair Value Measurement | Municipal Bonds	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	89,660	'
Estimate of Fair Value Measurement | Corporate Debt Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	53,089	'
Estimate of Fair Value Measurement | Commercial Paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	36,089	'
Estimate of Fair Value Measurement | Asset-backed Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	6,652	'
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	19,098	96,585
Contingent consideration	0	0
Level 1 | Municipal Bonds	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	0	'
Level 1 | Corporate Debt Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	0	'
Level 1 | Commercial Paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	0	'
Level 1 | Asset-backed Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	0	'
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	1,265	0
Contingent consideration	0	0
Level 2 | Municipal Bonds	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	89,660	'
Level 2 | Corporate Debt Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	53,089	'
Level 2 | Commercial Paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	36,089	'
Level 2 | Asset-backed Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	6,652	'
Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	0	0
Contingent consideration	14,177	7,358
Level 3 | Municipal Bonds	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	0	'
Level 3 | Corporate Debt Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	0	'
Level 3 | Commercial Paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	0	'
Level 3 | Asset-backed Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities, Fair Value	$0	'

FAIR_VALUE_MEASUREMENTS_Valuat

FAIR VALUE MEASUREMENTS Valuation (Details) (Level 3)	12 Months Ended
	Dec. 31, 2013
Minimum	'
Fair Value Inputs, Liabilities, Quantitative Information	'
Discount rate	3.10%
Maximum	'
Fair Value Inputs, Liabilities, Quantitative Information	'
Discount rate	13.50%

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$1,369	$2,024
Work in process	2,820	2,410
Finished goods	66,161	57,876
Total	$70,350	$62,310

PROPERTY_EQUIPMENT_Details

PROPERTY & EQUIPMENT (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and Equipment	'	'	'
Depreciation	$18,869	$17,640	$16,879
Property and equipment, gross	164,060	146,747	'
Less: accumulated depreciation	-99,910	-85,658	'
Total	64,150	61,089	'
Land	'	'	'
Property and Equipment	'	'	'
Property and equipment, gross	3,769	3,769	'
Building and improvements	'	'	'
Property and Equipment	'	'	'
Useful Life	'30 years	'	'
Property and equipment, gross	9,541	8,770	'
Equipment	'	'	'
Property and Equipment	'	'	'
Property and equipment, gross	14,588	13,320	'
Equipment | Minimum	'	'	'
Property and Equipment	'	'	'
Useful Life	'5 years	'	'
Equipment | Maximum	'	'	'
Property and Equipment	'	'	'
Useful Life	'7 years	'	'
Instruments	'	'	'
Property and Equipment	'	'	'
Useful Life	'3 years	'	'
Property and equipment, gross	107,867	95,739	'
Modules and cases	'	'	'
Property and Equipment	'	'	'
Useful Life	'3 years	'	'
Property and equipment, gross	22,325	19,045	'
Other property and equipment	'	'	'
Property and Equipment	'	'	'
Property and equipment, gross	$5,970	$6,104	'
Other property and equipment | Minimum	'	'	'
Property and Equipment	'	'	'
Useful Life	'3 years	'	'
Other property and equipment | Maximum	'	'	'
Property and Equipment	'	'	'
Useful Life	'5 years	'	'

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Compensation and other employee-related costs	$17,428	$16,733
Legal and other settlements and expenses	23,765	1,924
Accrued non-income taxes	2,938	473
Other	6,994	5,873
Total accrued expenses	$51,125	$25,003

DEBT_Details

DEBT (Details) (USD $)	12 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2007	31-May-11	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	Mortgages	Mortgages	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility
				Fluctuating Rate Per Annum	Fixed Rate	Fixed Rate	Fixed Rate	Letter of Credit
						Minimum	Maximum
Debt Instruments	'	'	'	'	'	'	'	'
Mortgage loan, final balloon payment	'	$5.10	'	'	'	'	'	'
Mortgage loan, term	'4 years	'	'	'	'	'	'	'
Credit facility, basis spread on variable rate	1.50%	'	'	0.75%	0.75%	'	'	'
Credit facility, current borrowing capacity	'	'	50	'	'	'	'	'
Credit facility, maximum borrowing capacity	'	'	$75	'	'	'	'	$25
Credit facility, variable rate	'LIBOR	'	'	'LIBOR	'LIBOR	'	'	'
Credit facility, period of variable rate	'	'	'	'1 month	'	'1 month	'3 months	'
Revolving credit facility, unused commitment fee percentage	'	'	0.10%	'	'	'	'	'
Revolving credit facility, minimum termination notice period	'	'	'10 days	'	'	'	'	'

EQUITY_Textuals_Details

EQUITY (Textuals) (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jul. 09, 2012

Aug. 03, 2012

Aug. 03, 2012

Aug. 03, 2012

Aug. 03, 2012

Dec. 31, 2013

Dec. 31, 2012

Aug. 03, 2012

Jun. 20, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 20, 2012

Dec. 31, 2013

Jun. 20, 2012

Jul. 30, 2012

Aug. 31, 2012

Aug. 31, 2012

Aug. 31, 2012

Aug. 31, 2012

Aug. 31, 2012

Aug. 31, 2012

Last Business Day of September 2014

Last Business Day of September 2015

Last Business Day of September 2016

Last Business Day of September 2017

Common Class A

Common Class A

Common Class A

Common Class A

Common Class B

Common Class B

Common Class B

Common Class C

Common Class C

Series E Preferred Stock

Issued by Company

Conversion of Class E to Class B

Conversion of Class B to Class A

Conversion of Class C to Class A

Conversion of Class B to Class A, Selling Stockholders

Equity Ownership of Less Than Ten Percent

Put Option

Put Option

Put Option

Put Option

votes

votes

Common Class A

Conversion of Class B to Class A

Class of Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares outstanding

93,442,753

91,270,064

'

'

'

'

'

'

66,065,197

63,892,508

'

'

27,377,556

27,377,556

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,691,245

'

'

'

'

'

'

Reverse stock split, conversion ratio

'

'

'

3.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Offering price per share (in usd per share)

'

'

'

'

'

'

'

'

'

'

$12

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized (in shares)

785,000,000

785,000,000

'

'

'

'

'

'

500,000,000

'

'

360,000,000

275,000,000

'

309,178,636

10,000,000

10,000,000

'

'

'

'

'

'

'

Common stock, votes per share

'

'

'

'

'

'

'

'

1

'

'

'

10

'

'

'

'

'

'

'

'

'

'

'

Shares sold for initial public offering (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,083,333

'

'

'

'

'

Stock repurchased (shares)

0

0

1,233,397

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of securities authorized for repurchase at shareholder's request under Put Agreement

'

'

'

'

25.00%

25.00%

25.00%

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from issuance initial public offering

'

$25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance Initial Public Offering, Net of Underwriting Fees and Offering Expenses

0

20,960,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from issuance of common stock

$7,555,000

$1,504,000

$886,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of stock, shares converted (shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,597,300

'

73,554

3,039,385

49,655,411

Conversion of stock, requirements, maximum ownership percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

EQUITY_Schedule_of_Issued_and_

EQUITY (Schedule of Issued and Outstanding Shares) (Details)	Dec. 31, 2013	Dec. 31, 2012
Class of Stock	'	'
Common stock, shares outstanding	93,442,753	91,270,064
Common stock, shares issued	93,442,753	91,270,064
Class A Common	'	'
Class of Stock	'	'
Common stock, shares outstanding	66,065,197	63,892,508
Common stock, shares issued	66,065,197	63,892,508
Class B Common	'	'
Class of Stock	'	'
Common stock, shares outstanding	27,377,556	27,377,556
Common stock, shares issued	27,377,556	27,377,556

STOCKBASED_COMPENSATION_Textua

STOCK-BASED COMPENSATION (Textuals) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Jul. 02, 2012	Jul. 02, 2012	Dec. 31, 2012	Dec. 31, 2012
	Stock Options	2012 Equity Incentive Plan	2012 Equity Incentive Plan	2012 Equity Incentive Plan	Reassessment Fair Value of Common Stock	Reassessment Fair Value of Common Stock	Original Fair Value of Common Stock	Original Fair Value of Common Stock
			Maximum	Common Class A	February 2, 2012 Grant	March 28, 2012 Grant	February 2, 2012 Grant	March 28, 2012 Grant
Share-based Compensation Arrangement by Share-based Payment Award	'	'	'	'	'	'	'	'
Shares reserved under the 2012 Equity Incentive Plan	'	'	'	6,246,075	'	'	'	'
Number of shares available for grant	'	'	10,769,230	4,453,236	'	'	'	'
Maximum contractual term	'10 years	'	'	'	'	'	'	'
Award vesting period (in years)	'4 years	'	'	'	'	'	'	'
Base number of shares that may be issuable under stock plan	'	3,076,923	'	'	'	'	'	'
Annual percentage limit for incremental shares that may be issued	'	'	3.00%	'	'	'	'	'
Exercise price per share granted	'	'	'	'	$12.06	$14.10	$10.34	$10.34
Unrecognized compensation expense, unvested stock options	$10.10	'	'	'	'	'	'	'
Weighted average period of recognition, unvested stock options	'3 years	'	'	'	'	'	'	'

STOCKBASED_COMPENSATION_Grant_

STOCK-BASED COMPENSATION (Grant Date Fair Values of Options Awarded to Employees) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'
Weighted average grant date per share fair value	$6.34	$5.90	$5.14

STOCKBASED_COMPENSATION_Fair_V

STOCK-BASED COMPENSATION (Fair Value of Options, Assumptions) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Risk-free interest rate, minimum	0.98%	0.90%	1.46%
Risk-free interest rate, maximum	1.74%	1.10%	2.65%
Expected volatility, minimum	41.00%	44.00%	46.50%
Expected volatility, maximum	44.00%	47.00%	47.00%
Expected term	'	'6 years	'6 years
Expected dividend yield	0.00%	0.00%	0.00%
Minimum	'	'	'
Expected term	'6 years 0 months 28 days	'	'
Maximum	'	'	'
Expected term	'6 years 4 months 16 days	'	'

STOCKBASED_COMPENSATION_Stock_

STOCK-BASED COMPENSATION (Stock Option Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'
Number of shares outstanding beginning balance	6,253	6,454	5,844
Number of shares granted	1,222	1,228	1,185
Number of shares exercised	-2,173	-1,061	-149
Number of shares forfeited	-416	-368	-426
Number of shares outstanding ending balance	4,886	6,253	6,454
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'
Weighted average exercise price per share outstanding beginning balance	$6.99	$5.14	$4.19
Weighted average exercise price per share granted	$14.78	$13.10	$10.86
Weighted average exercise price per share exercised	$3.48	$1.42	$4.13
Weighted average exercise price per share forfeited	$12.23	$9.55	$8.65
Weighted average exercise price per share outstanding ending balance	$10.04	$6.99	$5.14
Number of shares exercisable	2,821	'	'
Weighted average exercise price per share exercisable	$7.33	'	'
Weighted average remaining contractual life outstanding	'6 years 10 months 24 days	'	'
Weighted average remaining contractual life exercisable	'5 years 4 months 24 days	'	'
Aggregate intrinsic value outstanding	$49,528	'	'
Aggregate intrinsic value exercisable	$36,250	'	'

STOCKBASED_COMPENSATION_Compen

STOCK-BASED COMPENSATION (Compensation Expense Related to Stock Options and Their Intrinsic Values) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'
Compensation expense related to stock options	$5,177	$4,635	$3,286
Intrinsic value of stock options exercised	$25,034	$12,507	$969

INCOME_TAXES_Components_of_Inc

INCOME TAXES (Components of Income (Loss) Before Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Income before taxes, domestic	$101,424	$114,176	$97,677
Income/(loss) before taxes, foreign	577	477	-728
Income before income taxes	$102,001	$114,653	$96,949

INCOME_TAXES_Components_of_Pro

INCOME TAXES (Components of Provision for Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current Income Tax Expense	'	'	'
Current income tax provision, federal	$41,741	$40,338	$28,846
Current income tax provision, state	6,118	6,419	4,889
Current income tax provision, foreign	912	345	373
Current income tax provision	48,771	47,102	34,108
Deferred Income Tax Expense/(Benefit)	'	'	'
Deferred income tax provision/(benefit), federal	-14,088	-5,510	2,062
Deferred income tax (benefit), state	-1,210	-352	-52
Deferred income tax provision/(benefit), foreign	-84	-418	47
Deferred income tax provision/(benefit)	-15,382	-6,280	2,057
Income tax provision, total	$33,389	$40,822	$36,165

INCOME_TAXES_Reconciliation_of

INCOME TAXES (Reconciliation of Statutory U.S. Federal Tax Rate to Effective Rate) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Statutory U.S. federal tax rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	2.80%	2.90%	3.30%
Domestic production activities deduction	-3.50%	-2.30%	-1.50%
Tax credits	-1.70%	-0.10%	-1.00%
Nondeductible expenses and other	0.10%	0.10%	1.50%
Effective tax rate	32.70%	35.60%	37.30%

INCOME_TAXES_Components_of_Def

INCOME TAXES (Components of Deferred Income Taxes) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Components of Deferred Tax Assets [Abstract]	'	'
Inventory reserve	$19,635	$16,288
Accruals, reserves, and other currently not deductible	17,133	5,639
Stock-based compensation	5,152	4,913
Foreign net operating loss carryforwards	724	952
Total deferred tax assets	42,644	27,792
Valuation allowance	-327	-533
Total deferred tax assets, net of valuation allowance	42,317	27,259
Components of Deferred Tax Liabilities [Abstract]	'	'
Depreciation and amortization	-9,759	-9,993
Other	-1,229	-782
Total deferred tax liabilities	-10,988	-10,775
Net deferred tax assets	$31,329	$16,484

INCOME_TAXES_Reconciliation_of1

INCOME TAXES (Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Unrecognized tax benefits at the beginning of the year	$3,500	$2,799	$3,845
Additions related to current year tax positions	661	673	612
Additions related to prior year tax positions	64	46	22
Reductions related to prior year tax positions	-109	-18	-1,680
Lapse of statute of limitations	-138	0	0
Unrecognized tax benefit at the end of the year	3,978	3,500	2,799
Portion of total unrecognized tax benefits that, if recognized, that would affect the effective income tax rate	$1,184	$747	$591

INCOME_TAXES_Narrative_Details

INCOME TAXES (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Income Tax Examination	'	'
Benefit recorded in 2013 for reinstated 2012 tax credit	$0.90	'
Other Assets	'	'
Income Tax Examination	'	'
Long term deferred tax asset	$0.40	$0.40

LEASES_Minimum_Future_Rental_P

LEASES (Minimum Future Rental Payments Under Operating Leases) (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Leases, Operating [Abstract]	'
Year ending December 31, 2014	$733
Year ending December 31, 2015	422
Year ending December 31, 2016	262
Year ending December 31, 2017	102
Year ending December 31, 2018	46
Thereafter	43
Total	$1,608

LEASES_Rent_Expense_Related_to

LEASES (Rent Expense Related to Operating Leases) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Leases, Operating [Abstract]	'	'	'
Rent expense	$424	$419	$317

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Feb. 29, 2012

Dec. 31, 2011

Jul. 16, 2009

Jun. 30, 2011

Dec. 31, 2010

Sep. 30, 2006

Dec. 31, 2013

Jul. 31, 2011

Oct. 31, 2010

Dec. 31, 2013

Dec. 31, 2013

Oct. 31, 2010

Feb. 20, 2013

NUBONE

NUBONE

PIVOT Systems

PIVOT Systems

PIVOT Systems

Warsaw Orthopedic, Inc

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

NuVasive, Inc

Bianco

Minimum

Minimum

Minimum

claim

claim

claim

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

NuVasive, Inc

Altus Partners, LLC

claim

claim

claim

Loss Contingencies

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Damages awarded

'

'

'

'

'

$2,800,000

'

'

'

$16,000,000

'

'

'

'

'

'

Loss contingency accrual

'

'

'

'

1,000,000

'

'

3,000,000

'

'

'

'

'

'

'

'

Settlement agreement payment

'

'

'

1,000,000

'

'

3,000,000

'

'

'

'

'

'

'

'

'

Patent claims (number of claims)

'

'

'

'

'

'

'

'

9

'

3

3

'

1

1

1

Combined litigation loss

'

'

'

'

'

'

'

'

'

19,500,000

'

'

4,300,000

'

'

'

Provision for litigation loss - cost of goods sold

'

'

'

'

'

'

'

'

'

1,300,000

'

'

'

'

'

'

Provision for litigation litigation loss/(income)

$23,055,000

($786,000)

$1,470,000

'

'

'

'

'

'

$18,200,000

'

'

'

'

'

'

RETIREMENT_BENEFIT_PLANS_Detai

RETIREMENT BENEFIT PLANS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'	'	'
Nondiscretionary employee contribution match rate	100.00%	'	'
Maximum annual contribution match, per employee	$6,000	'	'
Maximum annual contribution match, percent per employee	3.00%	'	'
401(k) and other retirement plan contributions	$2,106,000	$1,055,000	$944,000

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Party Transactions [Abstract]	'	'	'
Accounts payable to related-party	$2,656	$2,556	'
Purchases from related-party supplier	$20,039	$20,159	$17,685

SEGMENT_AND_GEOGRAPHIC_INFORMA2

SEGMENT AND GEOGRAPHIC INFORMATION (Geographic Location) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
									segments
Revenues from External Customers	'	'	'	'	'	'	'	'	'	'	'
Number of reportable segments	'	'	'	'	'	'	'	'	1	'	'
Total sales	$115,245	$107,187	$107,009	$105,018	$100,536	$94,764	$95,977	$94,717	$434,459	$385,994	$331,478
United States	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers	'	'	'	'	'	'	'	'	'	'	'
Total sales	'	'	'	'	'	'	'	'	396,615	355,609	311,024
International	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers	'	'	'	'	'	'	'	'	'	'	'
Total sales	'	'	'	'	'	'	'	'	$37,844	$30,385	$20,454

SEGMENT_AND_GEOGRAPHIC_INFORMA3

SEGMENT AND GEOGRAPHIC INFORMATION (Products) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
									segments
									categories
Revenue from External Customer	'	'	'	'	'	'	'	'	'	'	'
Total sales	$115,245	$107,187	$107,009	$105,018	$100,536	$94,764	$95,977	$94,717	$434,459	$385,994	$331,478
Textuals [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Number of reportable segments	'	'	'	'	'	'	'	'	1	'	'
Number of product categories	'	'	'	'	'	'	'	'	2	'	'
Innovative Fusion	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer	'	'	'	'	'	'	'	'	'	'	'
Total sales	'	'	'	'	'	'	'	'	254,033	238,723	224,356
Disruptive Technology	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer	'	'	'	'	'	'	'	'	'	'	'
Total sales	'	'	'	'	'	'	'	'	$180,426	$147,271	$107,122

QUARTERLY_FINANCIAL_DATA_unaud2

QUARTERLY FINANCIAL DATA (unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Sales	$115,245	$107,187	$107,009	$105,018	$100,536	$94,764	$95,977	$94,717	$434,459	$385,994	$331,478
Gross Profit	88,471	81,872	82,248	81,525	80,979	75,892	77,598	76,326	334,116	310,795	262,682
Net income	$20,985	$20,310	$7,426	$19,891	$20,767	$16,487	$19,001	$17,576	$68,612	$73,831	$60,784
Net earnings per common share - basic	$0.22	$0.22	$0.08	$0.22	$0.23	$0.18	$0.22	$0.20	$0.74	$0.82	$0.69
Net earnings per common share - dilutive	$0.22	$0.22	$0.08	$0.21	$0.22	$0.18	$0.21	$0.19	$0.73	$0.80	$0.67

VALUATION_ACCOUNTS_AND_QUALIFY2

VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for doubtful accounts	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Beginning of period	$961	$602	$608
Additions	693	363	105
Write-offs	-73	-4	-111
End of period	1,581	961	602
Deferred tax valuation allowance	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Beginning of period	533	1,149	911
Additions	0	0	238
Write-offs	-206	-616	0
End of period	$327	$533	$1,149